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Abstract
Liposomes are promising agents for drug delivery. They have the ability to encapsulate
therapeutic drugs, resulting in decreased toxicity and prolonged circulation time. However, many
obstacles to achieving broad utility in liposomal drug delivery still exist, including the ability to control
release of therapeutic drugs and modulate surface reactivity. A primary focus of this dissertation
involves the development of synthetic photocleavable lipids for controlled release from membranes.
Phosphatidylcholine (PC) is a natural lipid that comprises the majority of structural membranes
in eukaryotes. It contributes heavily to the formation of lipid bilayers in cell membranes, and
modifications to the bilayer can induce membrane transitions and changes in permeability. As such, a PC
analogue has been developed with a photocleavable 2-nitrobenzyl acyl chain. This lipid (NB-PC) was
synthesized in nine steps from 4-(aminomethyl)benzoic acid and lyso-phosphatidylcholine (LPC). This
system is designed such that ultraviolet light degrades the fatty acid tail, changing the properties of the
liposomes they form and releasing entrapped hydrophobic molecules. This occurred in about half an
hour, as determined by a fluorescence assay involving the release of the dye Nile red.
Phosphatidylethanolamine (PE), cholesterol, and polyethylene glycol (PEG) were incorporated as
additives to examine the versatility of release from liposomes with varying membrane properties. It was
found that release remained robust regardless of lipid content. Furthermore, another photocleavable
lipid was developed containing an extended conjugated system, 2-nitrobiphenethyl, to enhance
photocleavage efficiency and enable two-photon release. This lipid, NBP-PC, was synthesized in seven
steps, and UV irradiation reached maximal release within five minutes.
This dissertation also describes molecules that have been synthesized or are in progress for
other projects. A nitrobenzyl-protected diacylglycerol has been synthesized, which is suitable for in situ
binding studies with DAG-binding proteins, such as protein kinase C (PKC). Also synthesized are a biotin–
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azide linker for anchoring molecules onto streptavidin-coated surfaces and various azobenzene
derivatives for studying chiral isomerization.
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Chapter 1 : Introduction to Drug Delivery
1.1 Diversity of Chemistry in Biological Systems
Biological systems contain a wealth of chemical variety. Within mammalian systems, these
compounds and structures are organized in four main categories: proteins, carbohydrates, nucleic acids,
and lipids. In each case, smaller units can aggregate or polymerize to form larger structures. (Figure 1.1)
Proteins are three-dimensional biopolymers consisting of amino acid subunits, and they are responsible
for enacting most biological functions that occur. Carbohydrates, on the other hand, are composed of
sugar molecules that serve as important building blocks for bodily tissues as well as sources of energy.
Nucleic acids are structures that form RNA and DNA, which are the genomic blueprints from which all
proteins are made. Finally, lipids compose biomolecules that encompass a wide variety of structures.
They are largely ampphiphilic molecules in which the organic and water soluble regions self-assemble to
form larger structures to become soluble. Lipid surfaces are the site for many biochemical reactions. 1
Lipids serve three main roles. The primary function is the formation of the plasma membrane
and organelle membranes, thus acting to separate for biological reactions.2 However, lipids are not
static structures, as they are additionally responsible for the storage of energy, especially through the
hydrolysis of triacylglycerols (TAGs), structures that act as reservoirs for fats.3 Furthermore, lipids serve
as secondary messengers for signal transduction thereby controlling important biological events.4
Protein–lipid binding interactions are critical in many biological pathways.5 There are a variety of classes
of lipids in which lipids activate protein function, including triacylglycerols, sterols, phospholipids, and
sphingolipids.3, 6
1.2 Lipid Structures and Roles
Phospholipids comprise a class of lipids that are related by their amphipathic properties, having
a glycerol backbone with a hydrophilic polar headgroup at the sn-3 position and hydrophobic nonpolar
fatty acid chains esterified to the hydroxyl groups at the sn-1 and sn-2 positions of glycerol (Figure 1.2).6
1

Amino Acid

Monoaccharide

Deoxyribonucleoside

Fatty acid

Protein
Carbohydrates
Nucleic acids
Lipid Membrane
Figure 1.1: Different chemical units and their hierarchical structure.
Larger biological entities, such as proteins, carbohydrates, nucleic acids, and membranes are
composed of smaller chemical building blocks.

2

The headgroup consists of the hydroxyl group of the glycerol backbone, often coupled to a phosphate
group, and the tail portion is composed of one or more fatty acids.6-7 Phospholipids commonly contain a
mixture of saturated and unsaturated lipid tails. Unsaturated tails tend to cause lipids to have more
freedom of motion in the membrane, whereas saturated tails lead to more rigidity.
All phospholipids are derivatives of diacylglycerol, which contains only a hydroxyl group at the
headgroup, yet is important for binding certain proteins responsible in growth pathways, such as protein
kinase C.8 Attaching a phosphate group to DAG produces phosphatidic acid (PA), which is also an
important signaling lipid. An even more diverse structural class of lipids is the phosphatidylinositol
polyphosphates (PIPns), which are vital to many biological pathways and can be phosphorylated at any
combination of the 3, 4, and 5 positions of the myo-inositol ring on the headgroup.9 While all the
previous are signaling lipids, responsible for protein localization, bulk lipids comprise the vast majority of
cellular membranes. The major bulk lipid is phosphatidylcholine (PC),6 but since the headgroups differ
among different lipids, this results in variation among lipids, affecting the shapes of the lipids as well as
their overall function. (Figure 1.3)
The major membrane lipid PC contains a phosphocholine group, which possesses a neutral
charge at physiological pH due to the positively charged quaternary amine and negatively charged
phosphate.10 Phosphatidylethanolamine (PE), on the other hand, contains an unmethylated nitrogen.
Due to this, the headgroup occupies a smaller area, and as a result, it disfavors bilayers, instead favoring
a negative curvature at higher concentrations within the membrane.11 This is useful for transient
processes such as membrane fusion.12 Phosphatidylserine (PS) is similar to PE, but with an additional
carboxylate group, resulting in an overall negative charge. It is a lipid known for binding certain proteins
as

well

as

acting

as

a

signaling

marker

3

for

cell

death.13

The

PIPns

Figure 1.2: Structure of a typical phosphatidylcholine lipid
The sn-3 position of glycerol is conjugated to a headgroup, in this case phosphocholine. The sn-1 and
sn-2 positions contain either a fatty acid tail with unconjugated double bonds (unsaturated) or
without any double bonds (saturated).

Figure 1.3: Examples of the main phospholipids.
Phosphatidylcholine (PC) comprises the majority of cellular membranes. Phosphatidylethanolamine
(PE) is important in fusion events. The phosphatidylinositol polyphosphates (PIPns) have multiple
phosphorylation patterns. Phosphatidylserine (PS) is prominent in apoptosis. Phosphatidylglycerol
(PG) is found in the lining of the lungs.

4

are interesting lipids because they are capable of multivalent protein binding, and exhibit different
biological properties depending on which combination of the 3, 4, or 5 hydroxyl groups is
phosphorylated.14 PA participates in fission and fusion, and it also is a signaling lipid for various proteins,
such as phosphatidylinositol 4-phosphate 5-kinase (PIP5K).14 Phosphatidylglycerol (PG) can be found in
the lining of the lungs.15 On their own, phospholipids will self-assemble in solution to form structures
made of lipid monolayers. In each monolayer, the polar headgroups are exposed to the aqueous
environment, and the nonpolar tails are arranged so that they avoid the aqueous solvent by aggregating
with other tails in the membrane. The precise membrane structures that are favored for each lipid
varies and will be discussed later.
Another class of lipids is the sphingolipids (Figure 1.4). These have ceramide (Cer) as their base,
which contains a hydroxyl group as the headgroup. The sphingolipids commonly contain two saturated
or mostly saturated chains. This leads to a structure that is overall taller and more rigid than that of
phosphocholine.16 The type main types of sphingolipids are sphingomyelin, which has a phosphocholine
headgroup, and glycosphingolipids, which contain at least one sugar conjugated to the headgroup.6
A third class of lipids is the sterols, which are biomolecules containing tetracyclic rings. The main
sterol essential to membranes is cholesterol (Figure 1.4). It stabilizes to membrane bilayers by adding
fluidity and abolishing the transition temperature at 30 mole percent cholesterol in the membrane.17
The transition temperature is the temperature at which liposomes transition to a stiff phase where lipids
have low mobility to a phase where lipids have high mobility and can mix more freely to become more
homogeneous. By abolishing the transition temperature, this results in bilayers that have the stiffness of
a solid phase, but with the mobility of a liquid phase.6 No more than 50% cholesterol should be included,
or else it will precipitate from the membrane. One of the key benefits of cholesterol is its ability to
rigidify the liposomal structure, minimizing leakage in studies.17

5

Figure 1.4: Ceramide lipids, the sterol cholesterol, and a triacylglyceride.
Ceramide, sphingomyelin, and glycosphingolipids are all types of sphingolipids. Cholesterol is a sterol
essential for membrane support. Triacylglycerides are important for energy storage.
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An additional class of lipids consists of the storage lipids, or fats. These include triglycerides
(Figure 1.4), sterol esters, and wax esters.18 They serve as energy stores and building blocks for the
formation of cellular membranes in the form of fat reservoirs.6 Energy is released upon hydrolysis of
their ester bonds. Defects in the production of these types of neutral lipids lead to diseases such as
diabetes and obesity.18
1.3 Types of Delivery Vesicles
As pharmaceutical research has progressed, a need became evident to develop methods for
delivering drugs with selectivity, since potent molecules that are toxic to diseased cells are often also
toxic to healthy tissues.19 Since A. D. Bingham discovered in the 1960s that lipids suspended in aqueous
dispersions formed bilayer structures called liposomes, they have been considered to be a promising
drug delivery system. One benefit is that liposomes can reduce toxicity by encapsulating the cytotoxic
chemical for release at the location of the diseased tissue or simply for a more gradual release in the
bloodstream.20 Liposomes are also versatile in that polar drugs can be carried in the internal aqueous
environment and nonpolar drugs can be carried in the liposomal tail region.20 Finally, lipids are
biocompatible and can avoid immune responses as they are natural biomolecules.
There are many issues, such as poor localization, specific release, off-site effects, and
elimination by the immune system21 that occur with unencapsulated or unconjugated drugs and can be
ameliorated by drug carriers. There is of course the liposome, which already has some drug formulations
on the market, such as DaunoXome (danorubicin) and Myocet (doxorubicin).22 Carbon nanotubes are
polycyclic structures that have high surface areas for attachment of drugs, proteins, or other
molecules.23 Cyclodexrins, another drug delivery system, are made by polymerizing glycopyranose units
and are promising for their low toxicity.24 Dendrimers are a specific type of polymer that have regular
branching

with

a

large

surface

area

7

for

functionalization25

(Figure

1.5).

Liposomes

Dendrimers

Carbon
Nanotubes

Nanoshells

Cyclodextrins

Polymeric
Micelles

Figure 1.5: Types of drug delivery carriers.
Liposomes can encapsulate hydrophobic drugs in the membrane or hydrophilic drugs in the aqueous
core. Micelles are only capable of hydrophobic entrapment. Polymerosomes, like ones made of
sugars, can also be used in drug delivery. Dendrimers, a type of center-grown polymer, are yet
another avenue. Also nanoshells and polymeric micelles have been used.
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1.4 Packing Parameters
In solution, lipids and charged amphiphilic surfactants can form self-assembled structures. Most
importantly, these self-assembled structures can vary depending on conditions,11a including
thermodynamic and entropic properties. Common structures lipids can form are spherical micelles,
cylindrical micelles, spherical bilayers, or planar bilayers.11a Micelles are single layer vessels that have
hydrophilic heads facing outwards and hydrophobic tails facing inwards. Bilayers, on the other hand,
have hydrophilic heads pointed toward both the outside and inside, with the two layers of tails facing
each other. This creates an aqueous core, as opposed to the oil-soluble centers of micelles. Other
structures are also possible, including reverse micelles, which have head and tails pointing in the
opposite direction of micelles.
The packing parameter ρ is used to describe the structural shape that leads to micelles or
𝑣

bilayers, and it is defined by 𝑎𝑙 where v is the volume, a is the cross sectional area of the headgroup, and
l is the length of the tail. When ρ is less than one third, a spherical micelle is formed. As the tail shortens
to the point that ρ is between one half and one third, rodlike micelles are formed in the inverted
hexagonal structure, favoring reverse micelles. Further on, a spherical bilayer is formed when ρ is
between one half and one, with more flexible bilayers generated at values closer to one half. The
spherical bilayer unfolds to a planar bilayer when ρ is one (Figure 1.6).11, 26
The choice of lipid used is important for forming the desired assembly. Lipid bilayers can be used
as carriers in the bloodstream, while at the same time encapsulating either hydrophilic or hydrophobic
drugs. For a vesicle to be formed, the surface tension must be high and the stretching ability of the
material low. This can occur for two tailed lipids, or even for lipids that have tails of different lengths.
Lipids such as PC favor spontaneous aggregation in aqueous dispersions into spherical bilayers, or
liposomes,

due

its

lack

of

net

9

charge

and

cylindrical

shape.27

Figure 1.6: Packing parameters of vesicle formation
Packing parameters help determine the optimal structure that will form based on the lipid structure.
For example lyso-phosphatidylcholine (LPC) has a large headgroup compared to the tail, so the
resultant shape is conical, and this favors micelles. Phosphatidylethanolamine (PE), with a nonmethylated headgroup, has a small headgroup compared to the tails, so it will have an inverted cone
shape, forming reverse micelles in organic solution or more complicated inverse hexagonal structures
in aqueous solution. Phosphatidylcholine (PC) forms bilayers due to the cylindrical shape it adopts.
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The one-tailed lysolipids, such as LPC, favors micelle formation. Additionally, phospholipids like PE with
smaller effective headgroups form reverse micelles as an inverted hexagonal structures in aqueous
solution, forming rod-like clusters. Lipids such as LPC, however, encourage the formation of micelles,
because of the smaller effective tail volume.28 For drug delivery, it is desirable to be able to incorporate
different types of lipids. Thus, it is ideal to develop delivery methods that are effective with a wide range
of lipids with different properties.
1.5 Liposomes and Considerations
One of most essential components to proper liposome formation is purity.29 Lipids can be
assayed for purity by thin layer chromatography (TLC) or high pressure liquid chromatography (HPLC).
There are several ways in which the impurities can be displayed, such as isomerization. For example, the
natural 1,2-diacylglycerol (DAG) has an equilibrium with its 1,3 isomer, whereby the ester linkage on the
sn-2 position migrates to the sn-3 position.30 The TLC will show this by the appearance of a spot slightly
higher on the TLC plate than the 1,2-isomer. Another way is by oxidative hydrolysis of lipids to lysolipids.
The main method of decomposition, however, is by oxidation of saturated lipid tails to peroxides. A
good precaution against oxidation is storing the lipids under an inert gas, under nitrogen or argon, and
storing the samples at -20° C or colder.29
Another feature of importance when considering to the choice of lipids in a liposome is the
transition temperature (Tc or Tm). Below this temperature liposomes are rigid and lipid diffusion is low.
Above this temperature liposomes are in the gel phase, and lipids are more fluid with higher mixing
diffusion. For initial formation of liposomes, a heat above the transition temperature should be applied
in order to obtain homogeneous mixtures of lipids within liposomes populations. For example, the Tm of
dioleyl phosphatidylcholine (DOPC) liposomes is -22° C, while liposomes consisting entirely of distearoyl
phosphatidylcholine (DSPC) have transition temperatures as high as 58° C.31 (Table 1.1) This
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Table 1.1: List of typical phospholipids and transition temperatures
Different types of phospholipids are designated by their chain length and saturation. For example,
DOPC contains 18-carbon fatty acid chains with one double bond between C9 and C10. The transition
temperature, which marks the division between the crystal and gel phase, rises with increasing length
and lowers with decreasing saturation. The type of headgroup also impacts the transition
temperature, as seen by comparing DOPC, DOPS, and DOPE. The designation is read as the carbon
length, followed by the degree of saturation in the type of fatty acid chains. For example, DOPC has
18-carbon chains with one π bond in each tail. If multiple π bonds exist, they are unconjugated in
natural lipids.

Designation Abbrev.

Transition
Temp.

[Data courtesy of Avanti Polar Lipids]
Dioleoyl phosphatidylcholine (DOPC)
Dioleoyl phosphatidylethanolamine (DOPE)
Dioleoyl phosphatidylserine (DOPS)
Dilauroyl phosphatidylcholine (DLPC)
Dimyristoyl phosphatidylcholine (DMPC)
Dipalmitoyl phosphatidylcholine (DPPC)
Distearoyl phosphatidylcholine (DSPC)
Distearoyl phosphatidylserine (DSPS)
Distearoyl phosphatidylethanolamine (DSPE)
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18:1
18:1
18:1
12:0
14:0
16:0
18:0
18:0
18:0

DOPC
DOPE
DOPS
DLPC
DMPC
DPPC
DSPC
DSPS
DSPE

-17
-16
-11
-2
24
41
55
68
74

demonstrates that as the lipid becomes more unsaturated, the transition temperature lowers. On the
other hand, the lengthening of the chains will raise the Tm.
1.6 Liposomal Properties
Typical liposomes contain first and foremost some amount of PC, because it is the major
component in cellular membranes and forms stable bilayers. The fatty acid tails of the lipids within
liposomes can potentially modulate membrane surface interactions via the formation of macrodomains
or microdomains. For example, Elegbede et al.32 found in studies that release of carboxyfluorescein
(CBF) from liposomes driven by the MMR-9 enzyme was more efficient with palmitoyl–oleyl
phosphatidylcholine (POPC) than DOPC liposomes, and DSPC liposomes showed little or no release of
encapsulated dye. McGregor et al. and Takahashi et al. demonstrated that liposomes containing lipids
with longer fatty acid chains exhibiting a greater degree of transfection across membranes.33 It is
theorized that triggered release properties of liposomes can be optimized by fatty acid composition.
Nadler et al. reported that binding of diacylglycerol (DAG) to a green fluorescent protein (GFP) was
enhanced with a stearyl–arachidonyl DAG compound and a stearyl–linoenyl DAG, while little or no
binding was observed with a palmitoyl–oleyl or dioctanoyl DAG.34 Besides PC lipids, PE lipids are at times
included in small percentages, again with different lengths and degrees of saturation. This serves as a
destabilizing agent for phase change events such as cell fusion,35 Cholesterol is known to stabilize lipid
bilayers against temperature effects, dampening the permeability of ions and small molecules.36
Another important consideration is the size of the liposome, which can vary from under 20 nm
in diameter to over 1 μm upon formation.31 Liposomes classified by size can be either small unilamellar
vesicles (SUV) if they are 50 nm or less or large unilamellar vesicles (LUV) if they are about 100 nm. They
can also be giant unilamellar liposomes (GUV) if they are over a micron in size. The lamelarity refers to
how many bilayers are present in the liposome.15 Typically unilamellar liposomes at sizes of 200 nm are
utilized for drug delivery in order to penetrate tumor fenestrae that occur to uncontrolled growth.37 At
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sizes larger than 100 nm and without further modifications, the liposomes begin to favor multiple
bilayers. These are termed multilamellar vesicles (MLVs).15, 17
Both the size and lamelarity of liposomes can be controlled by the method of preparation. The
main liposome preparation techniques are mechanical, such as hydration, sonication, freeze–thaws, and
extrusion. Hydration is the method in which an organic suspension of lipids is dried and then rehydrated
in an aqueous medium, vortexing them to give an aqueous suspension.15,

38

This is one of the first

techniques used, notably by Alec Bangham.39 Sonication is a method of using an ultrasonic probe in the
aqueous suspension until the liposomes are all of uniform size. ULVs are favored by a cycle of cold and
warm baths, also known as freeze–thaws. Furthermore, a liposome extruder, which passes the
liposomes through a polycarbonate membrane with preset pores, enhances the uniformity of size
distributions.15, 40
There are also a wide range of instrumental techniques for characterization of liposomes.15
Dynamic light scattering (DLS) measures the distribution of particle sizes via the angles of diffraction of
light from different particles in solution. Transmission electron microscopy (TEM) magnifies the
liposomes for visual confirmation of sizes, and it also shows the shapes and forms of liposomes. Tracking
the 31P signal with a lanthanide shifting agents can give an idea of the ratio of outer labeled phosphates
to inner ones, verifying if liposomes are unilamellar.41 Surface potential, which relates to the overall
charge of the inner and outer leaflet of the liposomes, can be tracked by zeta potential measurements.
Furthermore, there are assays for phospholipid concentration, osmolarity, and even animal toxicity to
characterize liposomes for various purposes.
Liposome stability and permeability is an important issue in liposome applications. In general,
liposomal size stays constant for approximately 48 hours. The permeability increases with decreasing
acyl chain length and decreasing saturation. An incorporation of at least 33% cholesterol helps prevent
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permeability dramatically.29 Certain lipids can furthermore only be incorporated below a certain
threshold. For example, at room temperature and under physiological pH the lipid PE can only be
incorporated up to 70% with PC before the self-assembly shifts to the inverted hexagonal structure.42
1.7 Types of Liposomes
There are four main types of liposomes used for drug delivery: conventional, cationic, stealth,
and targeted (Figure 1.7).43 The conventional liposomes have no protection and thus have low survival
times in circulation, being quickly uptaken by the reticuloendothelial system (RES) in mammalian
systems. A second type of liposome is a cationic liposome, which is used to complex with negatively
charged nucleotide drugs and for cell membrane transfection.44 Long-circulating liposomes (or stealth
liposomes) have polyethylene glycol (PEG) chains conjugated on the liposomes surface. This shields the
liposomes from proteins of the RES. It also prolongs the circulation time of liposomes dramatically.43, 45 A
popular method to attach the PEG chains is to conjugate them to the amine headgroup of a PE lipid.
Finally, there are immunoliposomes, which have antibodies conjugated to the liposome for targetspecific recognition, enabling precise delivery to diseased cells.43, 46
1.8 Antibodies and Their Use in Liposomal Systems
Antibodies are proteins of the immune system bred to specific antigens, like a lock and key.
Being such, they have been used for site-specific delivery of drugs. Antibodies can even be affixed to
liposomes for the purpose of targeted delivery.

These are called immunoliposomes, and they

demonstrate desirable features for drug-specific delivery, such as inhibition of tumor growth factors.47
Antibodies are best used to target sites where antigens are overexpressed so the healthy cells that
produce normal levels of those same antigens will not be targeted.48 Antibodies are utilized for high
binding and specificity, and with liposomes their binding does not change significantly when attached to
a liposomal surface.48
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Figure 1.7: Different types of liposomes
Conventional liposomes can be used to encapsulate drugs for delivery purposes. Cationic liposomes
are used for transfection of membranes. Stealth liposomes have polyethylene glycol (PEG) stranded
grafted on the surface to evade recognition by the immune system. Targeting liposomes contain
antibodies grafted onto the surface for specific targets.
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Though immunoliposomes can recognize targets, whole antibodies are easily recognized by the
MPS as foreign particles and are subsequently taken up by the liver and spleen for destruction,
especially if the liposome contains negatively charged headgroups such as phosphatidylglycerol (PG) or
phosphatidylserine (PS).28 For this reason, smaller portions of the antibodies are used, such as Fab’ or
scFv fragments. Fragment antigen binding, or Fab’, is developed by pepsin digestion of the antibody,
leaving the Y-shaped end of the antibody. Single-chain fragment variables, scFv fragments, on the other
hand, consist of the smallest portion of the antibody that contains the whole binding site, containing
thef heavy and light flexible chains of the antibody termini connected by a string of amino acid linkers.28,
49

Furthermore, adding a coating of 5—10% PEG2000 or PEG5000 on immunoliposomes tends to improve

the durability and delivery of these structures.28a, 48, 50 (Figure 1.8).
Antibody applications include targeting of macrophages that promote tumor growth51 and
targeting neovascular growth regions.47, 52 An example is tumor associated macrophages (TAMs), which
encourage growth of tumor cells upon uptake of immunoliposomes containing anionic lipids such as PG
and PS, after which the drugs are released and the macrophage is killed. Peptide coated and
manosylated liposomes can also aid in uptake.51 Antibodies are thus an essential part of modern drug
delivery systems.
1.9 Drug Delivery Obstacles
As pointed out earlier, many drugs that are intended for certain diseased areas can be toxic to
normal cells. Thus side effects are common if certain potent drugs are not localized to solely the
diseased area. An example is doxorubicin, which is toxic to the heart.37 A further complication of potent
drugs with the use of a carrier is fast clearance by the immune system. Additionally, many drugs are
hydrophobic, so they will precipitate in the bloodstream. Finally, many current drug carriers do not
exhibit efficient release of encapsulated molecules.
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Figure 1.8: Types of immunoliposomes.
Type A contains antibodies alone on the surface of the liposome. Type B has PEG chains and
antibodies both on the surface. Type C, which contains the optimal strategy, has antibodies
conjugated onto the distal end of the polyethylene glycol (PEG) liposomes.
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The use of delivery vessels solubilizes nonpolar particles in the hydrophobic region, and the
toxicity is subsequently decreased until released at the target site with a greater concentration at the
site of interest.53 Drug delivery vessels should be large enough to not be filtered by the kidneys, but also
small enough to advantageously utilize the larger fenestrae of the cancer tumor, which can range
between 600 to 800 nm in size.37
Several drugs have already been approved on the market as liposomal formulations for various
diseases.54 Among them are doxorubicin (for Kaposi’s sarcoma, ovarian cancer, breast cancer, and
myeloma), danorubicin (for Kaposi’s sarcoma and leukemia), and cytarabine (for certain leukemia and
lymphoma cases). Liposomes can cause certain negative effects on certain patients, such as skin
hypersensitivity and respiratory problems.55 These effects are more pronounced in formulations where
PEG chains are introduced. The effects of skin conditions are due to liposomal tendency to deposit onto
the skin while still holding encapsulated drugs in tumorous tissue as well as in the skin. However, the
side effects decrease substantially after the first round of treatments.
The optimization of drug carriers also involves many difficult tasks. If the lipids do not form a
tight seal, the encapsulated drug will leak before the liposomes reach the target site. It is also important
to protect the liposomes from recognition by the mononuclear phagocytic system (MPS), which includes
various structures of the immune system, such as more simple monocytes and professional
phagocytes.56 Additionally, disease localization could be enhanced if the liposomes passively aggregate
at the diseased tissues. This is achieved by grafting PEG strands on the liposomal surface. Finally,
liposomes that are very stable within the body have a tendency to have slow release times. This can be
circumvented by using a dependable triggering mechanism, such as a system that targets acidic regions
or introduces an external stimulus. All of these issues must be addressed in liposomal design if drug
delivery is to be successful.
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1.10

Types of Internal-Stimulated Release
Various types of stimuli have been used in conjunction with drug delivery systems. Stimuli-

responsive materials are beneficial for enhancing delivery to targeted diseased area. One reason for this
is that passive diffusion, also termed Fickian diffusion, progresses at the same rate for both diseased and
healthy site. Therefore distribution necessitates selective triggering in order to provide a focused
distribution.57 In terms of tumor targeting, PEGylation addresses this issue by shielding liposome from
opsonin-targeting of the immune system, thus prolonging circulation time to enhance the probability of
tumor penetration via the EPR effect.45a However, to further enhance this effect, or to induce treatment
equivalent to that of the free drug of the target, stimuli-induced release is beneficial. Different
approaches are available, including redox chemistry, enzymatic approaches, acidic release, and
magnetism.
One approach, redox effects, was used by Ong et al.58 with their liposomal system that included
a quinone–PE lipid (Figure 1.9). Cancer cells overexpress the quinone reductase, so under these
reducing conditions, quinone moiety will be reduced, and a cyclization will occur that liberates the
bilayer-disfavoring PE lipid. The liposomes will then undergo phase transition to micelles. A more
common route is the incorporation of disulfide bonds for the reductive cleavage of upregulated
glutathione in cancer cells. However, targeting specific redox release can be difficult, as illustrated by
the drug Celltech, which failed to produce therapeutic results after it was approved by the Food and
Drug Administration.57
Enzymatic approaches have also been employed to target overexpressed enzymes at diseased
sites. For example, since secretory phospholipase A2 is more active at tumor and inflammation sites,
Andresen et al.59 developed lipids with a PE–PEG headgroup and an ether and ester tail. In a liposome
formulation, the ester bond would be enzymatically cleaved and the cytotoxic ether lysolipids prodrug
would be released. This system is especially prone to hydrolytic cleavage since polymer coatings and
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liposome formulations are more prone to sPLA2 activity than lipid drugs alone. Because PEG coating may
slow passive release, enzyme-cleavable PEG attachments have also been synthesized, as with the
polyaminoacid coatings developed by Romberg et al.60 The targeting via enzymes overall requires an
intimate knowledge of the surface chemistry occurring at the diseased site.
Release using heat has been utilized by taking advantage of dilation of blood vessels, including
tumor vessels, that occur at lightly elevated temperature,61 in the range of 34 to 39 °C. Temperatures
below this range do not increase tumor permeability, and higher temperatures lead to damage in the
form of hemorrhage and stasis.62 Furthermore, liposome formulations have been developed with a Tc
around 44° C, such as the commercially available formulation ThermoDox (Celsion). These liposomes are
prone to a drastic leakage in the absence of cholesterol. Also, ultrasound63 has also been used in
conjunction with heat to visualize the release of particles, as in the case of Ranjan et al.64 to gain a better
understanding of thermal application to solid tumors. Additionally, heat can be used to cause an indirect
release of entrapped compounds, as with solutions that contain ammonium bicarbonate and release
carbon dioxide as a byproduct of mild hypothermia, thus perturbing the membrane.65
Furthermore, since tumors are typically slightly more acidic than the surrounding tissue, there
are numerous examples of acid-sensitive targeting examples. Acid-cleavable systems needs to enact a
drastic change with a slight pH change, since healthy tissues have a pH around 7.4 and tumor sites have
a pH of 6.5 to 7. One strategy is to develop acid-cleavable bonds, such as hydrazone bonds. Kale et al.66
developed an acid-cleavable lipid conjugate that effectively hydrolyzes at a pH of 5.5. Another type of
acid-sensitive strategy involves the protonation of certain residues. For example, tumor necrosis factor
alpha (TNFα) can be released by a protonation of amino acid residues, as shown by Deng. et al.67
Protonation of PE conjugated to PEG or poly(ethylene imine) leads to an increase in membrane
transfection efficiency.
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It should also be pointed out that these are only a few types of release. Others such as
ultrasound-mediated, magnetic, electric, glucose-mediated, and light also exist. Among these, light is of
special interest because it operates independently of internal cues or bodily mechanisms. This will be
the focus of our work and will be discussed in further detail in chapters two and three.
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Figure 1.9: Different types of liposome release systems
There are a variety of approaches for the passive triggered release of encapsulated cargo from
liposomal containers. The first example is suited for release of phosphatidylethanolamine in areas
overexpressing quinone reductases. Enzymatic approaches can be used to delivery ether prodrugs via
ester hydrolysis by secretory phospholipase enzyme A2. Acidic linkages, such as hydrozones, can be
cleaved under slightly acidic conditions. Finally, liposome formulations with lysolipids can tune a
thermal release at a slightly increased temperature slightly above body temperature.

23

Chapter 2 Phosphatidylcholine Analog Lipid (NB-PC) with Photocleavable 2-Nitrobenzyl sn-2 Acyl
Chain
2.1 Introduction
The previous examples of redox, heat, and enzymes in chapter one depend on the local
environment. In the case of tumors, these types of release take advantage of the local environment,
such as overexpressed enzymes or inducing larger vasculature. However, these measures do not allow
for external spaciotemporal control over release. One promising method that has been explored is the
use of light as an external stimulus, since it does not depend on the local environment, or on inducing a
change in the local environment. This penetration is an important feature in light-controlled therapy.
Light is fundamentally a form of energy. A lower the wavelength corresponds to a higher the
energy of the light is used, according to Plank’s law.

𝐸=

ℎ𝑐
𝜆

𝐸 = ℎ𝜐

or

(Eq. 2.1)

In this equation, E is the energy of a photon, c is the speed of light, ν is the frequency, and λ is the
wavelength. Light can give access to excited states that are not easily accessible otherwise. This is
especially important in terms of bond breaking, because light irradiation excites electrons into
antibonding orbitals. In respect to clinical trials, light penetration into the skin barrier depends on a
number of factors, including wavelength, duration, power, and skin pigment. For someone with fair skin,
a UV beam of 350 nm can penetrate 6 μm into the skin, while a beam of 700 nm can penetrate 750
μm.68
Light is an appealing source of release because it has easily controllable properties, such as
wavelength, intensity, duration, and localization.69 Light is used for many applications, including crosslinking in protein–lipid binding and photoaffinity labeling.70 It can also be utilized for the activation or
deactivation of certain molecules by decomposing photochemically-responsive moieties. For this
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purpose, light protecting groups (LPGs) have been synthesized. One of the more studied LPGs is the 2nitrolbenzyl group.71 Other groups include 7-nitroindoline, coumarin-4-ylmethyl, p-hydroxyphenacyl,
and nitrophenethyl (Figure 2.1).72
2.2 The o-Nitrobenzyl Protecting Group
With photo-release, chemical or biological substrates can be protected and then activated by
stable photolabile protecting groups, or cages.72 One of the first literature examples of caging is the
protection of ATP in 1978 by Kaplan and co-workers73 in order to study the mechanism of the sodium
and potassium ion pump. (Figure 2.2). The caged substrate (2.1) was irradiated to form the nitroso
byproduct (2.2) and ATP (2.3). Other substrates that can be protected range from biological
components, including nucleotides and peptides, to organic and inorganic substrates, such as calcium
ions, phosphates, and carboxylates.71 Lipids have also been added to the list of protected substrates in
the past few years.

74

These include diacylglycerol,75 phosphatidic acid,76 and phosphatidylinositol-

(3,4,5)-trisphosphate.77 It would be preferable to obtain a photo-release in the near IR region, because
this area of light limits damage to nucleic acids and proteins in the body. At present, however, photorelease of molecules tends to occur in the violet or near ultraviolet portion of the spectrum.19
Many other substrates have been successfully protected and released by the o-nitrobenzyl (oNB) moiety, such as serotonin,78 calcium,79 and choline.80 The mechanism of release for the o-NB
chromophore is well studied, and literature has provided ideas for increasing its usefulness for drug
delivery by shifting the wavelength to the near infrared (IR) region, where techniques such as twophoton excitation (2PE) are useful 81 and will be discussed in chapter 3.
The manner by which the o-NB group releases its substrate and becomes a nitroso byproduct
occurs by a chemical decomposition via a Norrish type II mechanism (Figure 2.3).82 The whole process
begins with excitation of 2.4, leading to a radical intermediate by electron promotion into the π* orbital
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2-Nitrobenzyl

7-Nitroindoline

Nitrophenethyl

p-Hydroxyphenacyl
Coumarin-4-ylmethyl
Figure 2.1: Different photoreactive groups
Used for caging a substrate until it is cleaved by photolysis. The 2-nitrobenzyl group is one of the
longer known and better understood LPGs.
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2.1

2.2

2.3
Figure 2.2: Light-induced cleavage of ATP from the o-nitrobenzyl group.
Caged ATP (2.1) is liberated by UV light, giving the nitroso byproduct (2.2) and ATP (2.3).
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to 2.5. From the singlet or triplet state, the radical on the oxygen abstracts hydrogen from the nearby
benzylic position, generating a resonance-stabilized benzylic radical (2.6). From the Z-nitronic acid
resonance intermediate (2.7), deprotonation occurs to the rate-determining aci-nitro (2.8) intermediate,
which is then deprotonated to form the E-nitronic acid (2.9), where the outer nitro oxygen is
protonated. Internal cyclization subsequently occurs, forming an oxazole intermediate (2.10).
Fragmentation of this intermediate proceeds through intermediate 2.11 before expulsion of the leaving
group to arrive at the nitroso aldehyde (2.12). When the enthalpy of expulsion of the leaving group is
less favorable or there is a sufficiently low pH, 2.11 is the product.71, 78
2.3 Photocleavable Liposomes
Several liposomes have been formulated with photoreactive groups, especially the nitrobenzyl
group (Figure 2.4). For examples, Zhang and coworkers42 formulated liposomes containing 50% PE and
50% of an o-NB-protected PE analogue (2.13). The o-NB lipids were stable for liposome bilayer
formation, just like PC. Under UV light, the o-NB groups were removed and the vesicles transitioned to
the inverse hexagonal phase, which is the favored structure for 100% PE structures. This approach has
the advantage of a very short synthesis, as a chloroformate version of the o-NB group can be purchased
to react with commercially available PE lipids. This system, however, still needs to be tested in biological
systems to validate if the nitrobenzyl is as biocompatible as a choline headgroup.
In another example, Nagasaki et al.83 developed a cationic amphiphile with a nitrobenzyl group
in the middle to enhance the transfection of pGL3 into COS-1 cells. Chandra et al.84 developed a single
chain amphiphile (2.14) that demonstrated release of fluorescein when formulated with PC lipids, while
Subramaniam85 devised a similar compound that instead include a photocleavable coumarin moiety
instead (2.15). All of these previous examples demonstrated that effectiveness of dye release are
influenced by the type of tails in the PC lipids. On the other hand, these compounds cannot be used
without aid of PC lipids, because both compounds are single-stranded amphiphiles that favor micelles.
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2.4

2.5

2.8

2.6

2.9

2.7

2.10

2.12
2.11
Figure 2.3: Photocleavage of the o-nitrobenzyl system
Irradiation of the conjugated nitrobenzyl compound (2.4) yields radical excitation of the N-O π bond
upon irradiation to diradical 2.5. Abstraction of the benzylic hydrogen gives 2.6, which is in resonance
with Z-nitronic acid 2.7. Next, a proton transfer via aci-nitro intermediate 2.8 yields E-nitronic acid 2.9.
Cyclization leads to oxazole 2.10. Deprotonation of this intermediate leads to nitroso 2.11, and
expulsion of the leaving group gives 2.12.
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2.14

2.16
2.15
Figure 2.4: Photocleavable amphiphiles developed by other groups.

Zhang et al.42 developed a liposomal system of 50% of 2.13 and 50% PC for release by a PE-driven
phase transition. Chandra et al.34b utilized 5% of 2.14 for carboxyfluorescein (CBF) release from
liposomes. This amphiphile was best for UV release, while 2.15 is a coumarin amphiphile meant for
two-photon release. A photo-induced based silica molecule was used with the isomerizable
azobenzene for mechanical release of the dye Nile red from the membrane.
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Dithiane lipids have also been used for liposome disruption under UV light by Wan and coworkers.86 They retain the phosphocholine headgroup, but this lipid has only been used at percentages
up to 20% in liposomes. Finally, azobenzene molecules have been used as an impeller mechanism by
Liang et al.87 with to release Nile red via trans–cis isomerism. These lipids produce cerasomes or silicamodified liposomes, but the effect of silica on living systems is still uncertain. Photocrosslinking has also
been used in the literature. Spratt et al.88 utilized PC lipids with polyunsaturated lipid tails so the
conjugated π bonds cross-link upon irradiation and form tight domains, forming space and causing the
entrapped dye to escape in the process
2.4 Discussion of Synthesis of NB-PC
For photocleavable liposomes that could be biocompatible, we sought to design and synthesize
a PC analogue (Figure 2.5) bearing a photocleavable moiety in the fatty tail (2.17, NB-PC). With the onitrobenzyl group, photocleavage would shorten the lipid chain (2.18), also producing aldehyde 2.19 as
a byproduct. This would alter the membrane properties, and stimulate release. Furthermore, the free
nitrogen could also potentially cyclize with the nearby ester to release lyso-phosphatidylcholine (LPC,
2.20), which does not favor bilayer formation on its own, as well as succinamide (2.21). This would cause
liposome disruption and subsequent cargo release.
A primary benefit of this system is that 2.17, also referred as NB-PC, bears a remarkable
resemblance to the natural PC. Because the headgroup is intact and the tails have the same ester
linkages, NB-PC should bear the same or similar biocompatibility and stability to natural PC in the
bloodstreams of living systems. Additionally, because the overall structure is similar to PC, which forms
stable membrane bilayers, the percent of NB-PC in liposomes that result in stable membranes should be
much more flexible than prior photocleavable analogues. Furthermore, it was expected that the o-NB
groups in the membrane could lead to a higher stability in the absence of light, due to π-π stacking.
Finally, as discussed previously, after irradiation of NB-PC, the photocleaved shortened tail of 2.18.
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2.21
2.19

2.17

2.18

2.20

Figure 2.5: Proposed Photocleavage of NB-PC in liposomes.
A. Photocleavage of 2.17 (also known as NB-PC) leads to shortening of the tail to 2.18 and aldehyde
2.19. Cyclization could also occur to 2.20, or LPC, and 2.20. B. The decomposition of NB-PC lipids in the
bilayer leads to reorganization/decomposition and simultaneous release of encapsulated molecules.
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(along with aldehyde 2.19) could induce some membrane defects. Furthermore, if cyclization occurs,
this would cause subsequent destabilization, because the formed LPC (2.20) will revert to the micellar
phase, as with the previous example of Zhang et al.42 Thus the NB-PC system is a widely tunable and
biocompatible system for stable liposome delivery and release.
The synthesis of NB-PC (Figure 2.6) began with commercially available 4-(aminomethyl)benzoic
acid 2.22 (Chem Impex International). The first several steps to 2.25 were carried out according to a
literature precedent.34b By first utilizing the reaction of 2.22 with trifluoroacetic anhydride (TFAA), the
benzyl amine was protected with an acid-stabile trifluoroacetamide protecting group to produce 2.23.
Next, nitration was carried out with a sulfuric–nitric acid mixture. The methylamine serves as an
ortho/para direction group, and the carboxylate group acts as a meta directing group, so nitration is
reinforced for the positions ortho to the aminoalkyl group in the product (2.24).
After nitration, the trifluoroacetyl (TFA) protecting group was removed and a tert-butyl
carbamate (Boc) group was introduced for 2.25, both under basic conditions. As a side note, the pH of
the solution upon removal of the TFA group (at least a pH of 8) must be sufficiently basic for the
deprotection to be successful. Therefore it is very important that after nitration, the product,
precipitated from ice, be thoroughly washed with water or extracted from a large quantity of water with
ethyl acetate in order to ensure removal of residual nitric or sulfuric acid. Upon addition of the tert-butyl
anhydride for the Boc protection, it is important to allow venting for at least the first 10 minutes for
evolution of carbon dioxide, which is one of the byproducts of both Boc protection and deprotection.
The Boc-protected product could in most cases be obtained after reaction completion (as
indicated by disappearance of the ninhydrin spot over the course of time) by a double extraction, first
washing the carboxylate with diethyl ether, then acidifying to the carboxylic acid and extracting with the
more polar organic solvent ethyl acetate. Any residual ethyl acetate peaks in the NMR spectra can be
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2.22

2.23

2.24

2.25

2.26
2.27
2.17
Figure 2.6: Synthesis of photocleavable lipid NB-PC
Protection of the amine of 2.22 led to compound 2.23. After this, nitration was carried out to produce
2.24. Protecting group exchange led to base stable 2.25. Elongation with hexylamine led to 2.26. Next
deprotection in acid and chain extension via ring opening of succinic anhydride produced 2.27.
Coupling of this compound to lyso-phosphatidylcholine (LPC, 2.20) resulted in cleavable lipid 2.17.
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diminished or removed by concentrating from dichloromethane several times. The next reaction was
carried out according to a previous procedure,34b but with a shorter alkyl amine for coupling than the
one used in the literature. Hexylamine was coupled to the carboxylic acid with hydroxybenzotriazole
(HOBt) and N,N,N’,N’-tretramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate) (HBTU),
which provided a modest result for 2.26. Attempts for coupling with dicyclohexylcarbodiimide (DCC) and
dimethylaminopyridine (DMAP) proved less fruitful. However, the diminished yield may be due to
unconverted starting material. Also, using the same procedure, the Boc-protected octadecylamine chain
was also produced. This was performed to vary the hydrophobicity of the lipid in case the hexylamine
chain of the original design was too short. After adding the hexylamine chain, the Boc group was
removed with trifluoroacetic acid (TFA) to give the free amine. This compound was basified through
extraction from a hydroxide solution and carried to the next step, the reaction with succinic anhydride
to furnish a carboxylic acid (2.27). This product, which is the full modified fatty acid tail, may utilize
workup by either column chromatography or recrystallization from diethyl ether to obtain product.
The final step involved coupling of the synthetic fatty acid 2.27 to commercially available lysophosphatidylcholine (LPC) from Avanti Polar Lipids with dicyclohexylcarbodiimide (DCC) and
dimethylaminopyridine (DMAP). Crushed glass from test tubes was included to increase the surface area
of reaction, since lipids tend to like to reaction on glass surfaces. Sonication was also used to speed up
the formation of 2.17. Both the glass and sonication were used according to the example of Rosseto et
al.89 Unreacted fatty acid 2.27 was collected from column chromatography when possible.
Other routes for the synthesis of 2.17 were also attempted (Figure 2.7). Route A entailed the
synthesis of the glycerolipid backbone after which the lipid headgroup could be introduced. This began
with (S)-glycerol acetonide (2.28). Using the Williamson ether synthesis, para-methoxybenzyl chloride
(PMB-Cl) was used to protect the free alcohol, producing 2.29. Catalytic acid produced the diol 2.30 in
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Figure 2.7: Alternative methods to photocleavable PC analogues.

A) Method producing enantiomerically pure 3.28 with ether tail at sn-2 position. B) Method for
racemic synthesis of an analogue with ether tail at sn-2 position. C) Enantiomerically pure method for
one step procedure for PC lipids bearing two ester-linked o-NB tails.
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83% over two steps. Protection of the primary alcohol with tert-butyldiphenylsilyl afforded 2.31. Further
work would include adding an ether tail via 2.32 to produce 2.33, and deprotection with
tetrabutylammonium fluoride to produce 2.34. Fatty acid 2.27 would then be coupled to 2.34 to
produce 2.35, followed by PMB deprotection with 2,3-dichlro-2,2-dicyanohydroquinone (DDQ) to 2.36,
and phosphoramidite chemistry with 2.37 to produce analog 2.38.
Another method was attempted, first condensing glycerol (2.39) and benzaldehyde (2.40) with
catalytic acid to form dioxane 2.41. An ether or ester tail could then be conjugated to the sn-2 hydroxyl
group. For example, an 18-carbon sulfonate (2.42) was used to produce 2.43. Then the remaining
alcohols were deprotected in methanolic acid to afford 2.44. Mono-acylation with 2.27 would then give
the racemic 2.36, and as before, phosphoramidite chemistry would afford racemic 2.38. Lastly, a route
with glycerophosphocholine (2.45) was attempted, where the photocleavable fatty acid tails can be
acylated directly from 2.27 with 2.462.27, which contains two o-NB tails (Figure 2.8 and Figure 2.9).
2.5 Discussion of NB-PC Studies
To test the photocleavage and encapsulation of these produced liposomes, a suitable dye assay
needed to be chosen. The best method for this approach was very similar to the example of cerasomes
described by Liang et al., which used Nile red.87 Nile red is a hydrophobic dye that favors lipophilic
environments, such as the bilayer membrane. It fluoresces in the membrane, and the fluorescence is
abolished upon precipitation in aqueous solution.
The dye 5(6)-carboxyfluorescein (CBF), which was initially utilized for the kinetic assay, is
hydrophilic and favors encapsulation in the aqueous liposome interior. In this assay, a 50 mM CBF
solution was utilized, and it also contained 150mM sodium chloride to mimic physiological osmolarity
and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), buffered at a pH of 7.40. This
CBF solution was hydrated with the liposomes, and later free CBF was separated from liposome-
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Figure 2.8: Fluorescence decrease from the release of Nile red from lipid membranes
The fluorescence of Nile red is diminished as it is expelled from the membrane over the course of 90
minutes.
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Figure 2.9: Plot of decreased fluorescence of Nile red over time.
The decrease of the fluorescence of Nile red in response to irradiation-induced expulsion produces a
curve similar to that shown above, which can be fit to an exponential decay equation of form
Equation 2.1.
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The dye 5(6)-carboxyfluorescein (CBF), which was initially utilized for the kinetic assay, is
hydrophilic and favors encapsulation in the aqueous liposome interior. In this assay, a 50 mM CBF
solution was utilized, and it also contained 150mM sodium chloride to mimic physiological osmolarity
and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), buffered at a pH of 7.40. This
CBF solution was hydrated with the liposomes, and later free CBF was separated from liposomeencapsulated CBF by a Sephadex G-50 size exclusion column loaded in a 50 mL syringe and packed with
a solution of 150 mM sodium chloride and 20 mM HEPES. The design of this assay was to first
encapsulate quenched CBF in the liposomes at 50 mM. Upon release from the liposomes with the
detergent sodium dodecylsulfate (SDS), the detergent Triton X, or irradiation with 350 nm light, a drastic
increase in fluorescence would occur. This assay, however, was not useful, because it was
experimentally determined that photobleaching occurred regardless of liposome composition. This was
exemplified by an overall decrease in fluorescence. This was attributed to the absorbance of CBF at 492
nm being too close to the irradiation wavelength applied to the sample at 350 nm. The deciding
experiment was an irradiation of CBF alone, which led to a decrease in fluorescence due to
photobleaching, rather than a steady signal. It is also likely that release from the aqueous interior was
not effective, leading to minimal signal change.
For the Nile red assay, each lipid used was diluted with 500 μL of chloroform. Enough solution
was aliquoted into a fresh vial to reach 5 mM of total lipids in a 500 μL solution. Nile red solution was
added based on a 250 μM calculation in 500 μL. The lipids and dye were dried under nitrogen and
vacuum in the same vial and after a few hours rehydrated with 500 μL of deionized water from a MilliQ
system. For specific examples see the experimental section. Liposomes were prepared per the normal
procedure, which include heating at 60° C for 1 hour, with intermittent vortexing, then 10 freeze–thaw
cycles, and finally 21 passes through a 200 nm extruder. After dilution to a usable range in the
fluorimeter, three milliliters were used in two different samples, and the fluorescence of Nile red was
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monitored as a function of time using a Perkin–Elmer fluorimeter. After every five minutes of irradiation,
the fluorescence was scanned (λex = 553 nm, λem = 614 nm). If the Nile red was released from the
membrane, the maximum fluorescence decreased. This decrease is caused by precipitation of Nile red
from the membrane bilayer into the aqueous solution. As an example, the data of the fluorescence of 5
mM of NB-PC only with Nile red encapsulated in the membrane was recorded. (Figure 2.8). The
maximum fluorescence was subsequently plotted as a function of irradiation time with 350 nm light
over the course of 90 minutes (Figure 2.9). The data was fitted to an equation for exponential decay.
Y = yo +Ae-kt ,

(Eq. 2.1)

In the above equation, Y is the % of initial fluorescence, yo and A are fit parameters, and k is the first
order constant. The half-life (t1/2) can then be calculated by the equation:
t1/2 = 0.693/k.

(Eq. 2.2)

In the first study, we evaluated the release from liposomes composed of 100% NB-PC. Several
controls were also performed. Irradiation of the 100% NB-PC sample led to an 80% decrease in
fluorescence over approximately 60 minutes (Figure 2.8 to Figure 2.10 and Table 2.1). On the other
hand, when liposomes composed of 100% NB-PC were kept in the dark or when the natural lipid DOPC
comprised 100% of the liposomes either in the light or dark, there was minimal release. These results
demonstrate that NB-PC is indeed responsive to UV irradiation and useful for the release of hydrophobic
small molecules from the membrane. Also, liposomes composed of the NB-PC lipid are stable in the
dark. Data fitted to Equation 2.1 and calculated according to Equation 2.2 are tabulated in Table 2.1.
Secondly, the effect of percentage of NB-PC in the liposome was tested, ranging from 10% to
50% (Figure 2.11 and Table 2.2). Additionally, 50% DOPE was included and the remainder of the lipids
was DOPC. The importance of including DOPE is that it will not favor bilayer membranes on its own or in
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Figure 2.10: Irradiation of 100% NB-PC and 100% DOPC and dark controls
Under UV light, NB-PC liposomes exhibited a decrease in fluorescence due to expulsion of Nile red
from the membrane. Controls were performed without light, without photocleavable lipids (DOPC
only), or both. Only minimal decrease in fluorescence from passive leakage occurred.

Table 2.1: Irradiation of 100% NB-PC and 100% DOPC, along with dark controls
Data from Figure 2.10 was fitted to Equation 2.1 and tabulated using Equation 2.2

Light
Dark

% NB-PC
100
0
100
0

% DOPC
0
100
0
100

yo
0.2053
0.8432
0.8074
0.8454

A
0.8848
0.1481
0.1863
0.1412
42

k (min-1)
5.07E-02
9.17E-02
2.90E-02
4.76E-02

k (s-1)
8.45E-04
1.53E-03
4.83E-04
7.93E-04

R2
0.9628
0.4233
0.8597
0.3813

t1/2 (s)
13.7
7.56
23.9
14.6

Figure 2.11: Variation of NB-PC in liposomes with 50% DOPE and remainder DOPC
NB-PC is utilized at different percentages within the liposome, from 10% to 100%. An increasing
percentage of NB-PC leads to greater release of Nile red. Thus this liposome system is tunable across
all percentages.

Table 2.2: Regression data for variation of NB-PC in liposomes with 50% DOPE and remainder DOPC
The data for Figure 2.11 is tabulated using Equation 2.1 and Equation 2.2.

Light

Dark

% NB-PC
10
25
50
100
10
25
50
100

% DOPE
50
50
50
0
50
50
50
0

% DOPC
40
25
0
0
40
25
0
0

yo
0.6450
0.5180
0.3845
0.2053
0.8278
0.8725
0.8738
0.8074

A
0.3592
0.4980
0.6302
0.8848
0.1628
0.1194
0.1159
0.1863
43

k (min-1)
8.08E-02
6.78E-02
4.53E-02
5.07E-02
6.46E-02
5.66E-02
4.17E-02
2.90E-02

k (s-1)
1.35E-03
1.13E-03
7.55E-04
8.45E-04
1.08E-03
9.43E-04
6.95E-04
4.83E-04

R2
0.9569
0.9614
0.9853
0.9628
0.7013
0.8070
0.4473
0.8597

t1/2 (s)
8.58
10.2
15.3
13.7
10.7
12.2
16.6
23.9

high percentages with PC, and may therefore enhance release. In this case, it was found that increasing
percentage of NB-PC led to increased release of Nile red from the membrane. Thus NB-PC is tunable
over a wide range of concentrations. Again, NB-PC only exhibited release of Nile red under UV light.
100% NB-PC was superimposed in Figure 2.11 for comparison.
The effect of PE addition to liposomes was tested to see if more PE conferred greater liposome
instability, since PE is a non-bilayer forming lipid and promotes negative curvature (Figure 2.12 and
Table 2.3). Again, NB-PC only exhibited release of Nile red under UV light, and studies using 100% NB-PC
were superimposed for comparison. It was thought that the percentage of PE enhances liposome
destabilization and release. Therefore, by increasing the percentage of PE, an enhanced release may be
observed, or liposomes may not form. For this experiment, 50% NB-PC was used, and 0 to 50% PE was
tested, with DOPC as the remaining lipid up to 100%. The curve for 100% NB-PC was superimposed
again. The results illustrated that PE has little effect on liposomal release from NB-PC liposomes for the
percentages used. Additionally, no effect was found from samples kept in the dark.
Next, the effect of cholesterol on liposomal release was tested, to determine if the formulation
was more stable with added cholesterol (Figure 2.13 and Table 2.4). Cholesterol favors bilayer
formation, so a higher amount of cholesterol may display greater stability in the dark, which would be
evident by a diminished release in the dark or under irradiation. Cholesterol percentages ranging from
0% to 50% were used with 50% NB-PC, with DOPC as the remainder lipid content. 100% NB-PC was
superimposed for comparison. No clear trend was again observed, showing that NP-PC is compatible
with the use of cholesterol. This further demonstrates that cholesterol has little effect on release from
NB-PC liposomes. It is beneficial that this system tolerates a wide range of lipids with different
properties, so the liposome used for delivery can be easily tuned for optimal release.
Lastly, since liposomes can have longer circulation times with the inclusion of polyethylene
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Figure 2.12: Effect of DOPE on liposomal release and dark controls
DOPE lipids, which are non-bilayer forming, were incorporated into liposomes from 10% to 50%.
Additionally, 50% NB-PC was incorporated for all samples. The difference was minimal among all
samples.

Table 2.3: Effect of DOPE on liposomal release and dark controls
Data was tabulated from Figure 2.12 using Equation 2.1 and Equation 2.2.
% NB-PC

% DOPE

% DOPC

yo

A

k (min-1)

k (s-1)

R2

t1/2 (s)

Light

50
50
50
50
100

0
10
25
50
0

50
40
25
0
0

0.3202
0.3268
0.3358
0.3845
0.2053

0.7140
0.7112
0.7226
0.6302
0.8848

6.13E-02
6.17E-02
5.06E-02
4.53E-02
5.07E-02

1.02E-03
1.03E-03
8.43E-04
7.55E-04
8.45E-04

0.9877
0.9844
0.9616
0.9853
0.9628

11.3
11.2
13.7
15.3
13.7

Dark

50
50
50
50
100

0
10
25
50
0

50
40
25
0
0

0.8542
0.8877
0.8074
0.8738
0.8074

0.1418
0.1037
0.1863
0.1159
0.1863

2.88E-02
3.57E-02
2.90E-02
4.17E-02
2.90E-02

4.80E-04
5.95E-04
4.83E-04
6.95E-04
4.83E-04

0.8591
0.6430
0.8597
0.4473
0.8597

24.1
19.4
23.9
16.6
23.9
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Figure 2.13: The effect of cholesterol on liposomal release
Cholesterol, which stabilizes bilayer formation, were introduced into 50% NB-PC liposomes, from 10%
to 50%. No significant difference was observed for all samples.

Table 2.4: Regression data for the effect of cholesterol on liposomal release
Data from Figure 2.13 was tabulated using Equation 2.1 and Equation 2.2.

Light

Dark

% NB-PC

% Chol

% DOPC

yo

A

k (min-1)

k (s-1)

R2

t1/2 (s)

50
50
50
50
100
50
50
50
50
100

0
10
25
50
0
0
10
25
50
0

50
40
25
0
0
50
40
25
0
0

0.3202
0.3024
0.3189
0.2821
0.2053
0.8542
0.8718
0.8564
0.8707
0.8454

0.7140
0.7350
0.7241
0.7808
0.8848
0.1418
0.1168
0.1281
0.1211
0.1412

6.13E-02
6.00E-02
5.65E-02
5.84E-02
5.07E-02
2.88E-02
3.35E-02
2.98E-02
1.84E-02
4.76E-02

1.02E-03
1.00E-03
9.42E-04
9.73E-04
8.45E-04
4.80E-04
5.58E-04
4.97E-04
3.07E-04
7.93E-04

0.9706
0.9827
0.9829
0.9589
0.9628
0.8591
0.5715
0.5379
0.6046
0.3813

11.3
11.6
12.3
11.9
13.7
24.1
20.7
23.3
37.7
14.6
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glycol (PEG) chains, we decided to study liposomes including 15% of PEG–PE lipids, which is on the
higher order of PEG used in liposome delivery formulations. We compared this data (Figure 2.14 and
Table 2.5) to 100% NB-PC and found little difference. Thus, NB-PC liposomes are tunable over a wide
range of different lipid compositions and properties. They can tolerate lipids that stabilize bilayers, lipids
that destabilize bilayers, and PEG lipid conjugates for protection from the immune system.
Dynamic light scattering spectra were also taken of different liposome samples, before and after
photocleavage, to visualize any size changes. Representative samples shown in the appendix include
those composed of 100% NB-PC both kept in the dark and irradiated at 350 nm for 90 minutes (Spectra
2.30 and Spectra 2.31). A slight size increase was seen in the average diameter, which could be random
fluctuation, or it could infer that the liposomal size is increasing, for example due to a fusion event.
2.6 Conclusion
A photocleavable analogue of phosphatidylcholine has been synthesized in eight steps. This 2nitrobenzyl-containing lipid forms liposomes over all percentages. It undergoes structural modification
with ultraviolet irradiation, releasing entrapped Nile red into the aqueous solution in response to a
change in the morphology of the lipids in the membranes. This photodisruptable liposome is widely
tunable, tolerating at least 50% of the bilayer disfavoring lipid PE, 50% of the the bilayer favoring
cholesterol, and also polyethylene glycol-conjugates up to at minimum 15%. Thus the PEG addresses
drug delivery issue of extending circulation time and shielding from the immune system, while this
remote light-triggerable system addresses the issue of efficient release. Future studies can study the
impact of antibodies affixed onto the end of the PEG chains for targeting to cells to further validate the
usefulness of this system.
2.7 Materials and Methods
Reagents and solvents were generally purchased from Acros, Aldrich or Fisher Scientific and used as
received. Palmitoyl–lysophosphatidylcholine and DSPE–PEG(2000) amine were purchased from
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Figure 2.14: Effect of polyethylene glycol on liposomal release
For drug delivery purposes, PEGylated PE lipids were incorporated into NB-PC liposomes at 15% of the
total lipid. Results were similar to 100% NB-PC liposomes.

Table 2.5: Regression data from effect of PEG on liposomal release
Data from Figure 2.14 was tablulated using Equation 2.1 and 2-2.

Light
Dark

% NB-PC
100
85
100
85

% PEG-PE
0
15
0
15

yo
0.2053
0.2150
0.8074
0.8581

A
0.8848
0.8561
0.1863
0.1317
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k (min-1)
5.07E-02
4.24E-02
2.90E-02
5.30E-02

k (s-1)
8.45E-04
7.07E-04
4.83E-04
8.83E-04

R2
0.9628
0.9700
0.8597
0.7304

t1/2 (s)
13.7
16.3
23.9
13.1

Avanti Polar Lipids, Inc. (Alabaster, AL) and (4-methylamino)benzoic acid was purchased from Chem
Impex International (Wood Dale, IL). Dry solvents were obtained from a Pure Solv solvent delivery
system purchased from Innovative Technology, Inc. Column chromatography was performed using 230400 mesh silica gel purchased from Sorbent Technologies. NMR spectra were obtained using a Varian
Mercury 300 MHz or Varian NMR 500 MHz spectrometers. Mass spectra were obtained with a JEOL
AccuTof DART or a JEOL AccuTOF ESI spectrometer with high resolution capabilities. Optical rotations
were measured with a Perkin–Elmer 241 Polarimeter using the sodium D line. Ultrapure water was
purified via a Millipore water system (≥ 18 MΩ·cm) triple water purification system. 4-(((Tertbutoxycarbonyl)amino)methyl)-3-nitrobenzoic acid was synthesized from (4-methylaminol)benzoic acid
according to a prior literature procedure.74 Detection of Nile red emission decreases attributed to
release was performed using a Perkin–Elmer LS55 fluorescence spectrometer. Samples were irradiated
with a Rayonet Preparative Type RS photoreactor while suspended in a cuvette with Pyrex as a filter.
4-((2,2,2-Trifluoroacetamido)methyl)benzoic acid. Compound 2.23.

2.22

2.23
Commercially available p-aminomethylbenzoic acid (2.22, 2.03 g, 13.5 mmol) was slowly added
to 6 mL of trifluoroacetic anhydride, cooled to 0° C. After addition, the reaction was allowed to warm
slowly to room temperature, at which point the reaction became homogeneous. After two hours, ice
cold water was added, which caused precipitation of the crude product. This solid was rinsed with ice
cold water and filtered. The crude was then extracted using ethyl acetate in three portions (3 x 100 mL)
from water. The combined organic layer was dried with magnesium sulfate and filtered, and then
concentrated using rotary evaporation. The product was redissolved with dichloromethane (3 x 100 mL)
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and reconcentrated, then dried under vacuum to give 3.04 g of product 2.23 as a white solid (91%), and
the characterizations matched previous literature.74
1

H NMR (500 MHz, DMSO-d6) δ: 12.93 (s, 1H), 10.08 (t, J=6.1 Hz, 1H), 7.93 (d, J=8.3 Hz, 2H), 7.39

(d, J=8.3 Hz, 2H), 4.46 (d, J=6.1 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ: 172.22, 147.61, 135.02, 134.75,
134.08, 132.56, 122.31, 47.54.
3-Nitro-4-((2,2,2-trifluoroacetamido)methyl)benzoic acid. Compound 2.24.

2.23
2.24
To 50 mL of concentrated sulfuric acid was added 2.23 (2.96 g, 12.0 mmol) at 0° C. A mixture of
10 mL of 1:1 sulfuric acid to nitric acid was added dropwise via addition funnel. After completion of
addition, the reaction was stirred for two hours and then poured into ice, causing precipitation. The
resultant solid was filtered and rinsed with ice cold water on a filter. The crude was then extracted using
ethyl acetate (3 x 100 mL) from water. The combined organic layer was dried with magnesium sulfate
and filtered, and then concentrated using rotary evaporation. The product was redissolved with
dichloromethane (3 x 100 mL) and concentrated, then dried under vacuum to give 3.12 g of product
2.24 as a slightly yellow solid (89%), with characterizations matching literature data.74
1

H NMR (500 MHz, DMSO-d6) δ: 10.12 (t, J=5.6, 1H), 8.54-8.41 (m, 1H), 8.25 (dd, J=7.9, 1.9 Hz,

1H), 7.63 (dd, J=8.2, 3.1 Hz, 1H), 4.77 (d, J=5.2 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ: 166.97, 158.35,
149.56, 147.40, 138.00, 135.22, 133.09, 131.74, 41.82.
4-(((tert-Butoxycarbonyl)amino)methyl)-3-nitrobenzoic acid. Compound 2.25.
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2.25
2.24
To 2.24 (1.04 g, 3.56 mmol) was added potassium carbonate (1.24 g, 8.97 mmol) and 10 mL of a
1:1 mixture of methanol–water. The pH was tested via litmus paper and was found to be a pH of at least
8. After stirring overnight, the solvent was concentrated on a rotary evaporator. The resultant crude was
dissolved in 24 mL of a 1:1 mixture of dioxane–water. Then di-tert-butyl dicarbonate (1.18 g, 5.41 mmol,
1.5 eq) was added, dissolved in 10 mL of the solvent, and the reaction was stirred for three hours. The
solvent was again concentrated on a rotary evaporator. The crude was then diluted with 100 mL of
water and washed with diethyl ether (3 x 100 mL). Afterwards, 10% citric acid was added dropwise until
a pH of 3 was achieved, and the aqueous portion was extracted with ethyl acetate three times. The
combined organic layers were then dried with magnesium sulfate, filtered, concentrated with rotary
evaporation and dried under vacuum to 981 mg of product 2.25 as a yellow solid (93%) over two steps,
and characterizations matched literature procedures.74
1

H NMR (300 MHz, CDCl3) δ: 8.73 (s, 1H), 8.29 (d, t=7.8 Hz, 1H), 7.75 (d, J=8.0 Hz, 1H), 5.36 (s,

1H), 4.65 (d, J=6.5 Hz, 2H), 1.44 (s, 9H). 13C NMR (126 MHz, CDCl3) δ: 166.97, 158.35, 149.56, 147.40,
138.00, 135.72, 133.09, 131.74, 127.06, 41.82.
tert-Butyl (4-(hexylcarbamoyl)-2-nitrobenzyl)carbamate. Compound 2.26.

2.25
2.26
To 2.25 (1.67 g, 5.64 mmol) of compound, dissolved in 350 mL of chloroform, was added
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diisopropylethylamine (2.95 mL, 16.9 mmol), hydroxybenzotriazole (0.229 g, 1.69 mmol,), and O(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (2.78 g, 7.33 mmol). After 30
minutes, hexylamine (2.24 mL, 16.9 mmol) was added. The reaction was then allowed to stir overnight,
after which it was washed with 100 mL of water, and the aqueous portion was extracted with
chloroform (2 x 100 mL). The organic layers were then combined and washed with saturated sodium
chloride, dried with magnesium sulfate, filtered and concentrated by rotary evaporation. Column
chromatography using gradient elution with 25–50% ethyl acetate/hexanes gave 1.13 g of orangeyellow product 2.26 (53%). Rf = 0.18 (25% ethyl acetate/hexanes).
1

H NMR (300 MHz, CDCl3) δ: 8.33 (d, J = 1.8 Hz, 1H), 7.92 (dd, J = 8.0, 1.9 Hz, 1H), 7.54 (d, J = 8.1

Hz, 1H), 7.01 (t, J = 5.9 Hz, 1H), 5.55 (t, J = 6.5 Hz, 1H), 4.53 (d, J = 6.5 Hz, 2H), 3.40 (q, J = 7.0 Hz, 2H),
1.58 (m, 2H), 1.40 (s, 9H), 1.35 – 1.22 (m, 6H), 0.86 (t, J = 6.8 Hz, 3H). 13C NMR (300 MHz, CDCl3) δ:
165.01, 156.07, 147.69, 137.61, 135.15, 132.17, 130.89, 123.68, 80.16, 42.26, 40.51, 31.56, 29.51, 28.40,
26.75, 22.62, 14.10. HRMS-DART: [M-H]- calcd for C19H29N3O5, 378.2034; found 378.2018.

tert-Butyl (4-(octadecylcarbamoyl)-2-nitrobenzyl)carbamate. Compound 2.47.

2.25

2.47

To 1.12 g (3.78 mmol) of compound 2.26, dissolved in 40 mL of chloroform, was added
diisopropylethylamine (DIEA, 3.30 mL, 18.9 mmol), hydroxybenzotriazole (HOBt, 509 mg, 3.77 mmol),
and O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU, 1.43 g, 3.78
mmol,). After 30 minutes, octadecylamine (2.03 g, 7.53 mmol) was added. The reaction was then
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allowed to stir overnight, after which 100 mL water was added, and it was extracted with chloroform (2
x 100 mL). The organic layers were then combined and washed with saturated sodium chloride, dried
with magnesium sulfate, filtered and concentrated by rotary evaporation. Column chromatography
using gradient elution with 10–25% ethyl acetate/hexanes gave 3.56 g of orange-yellow product 2.47
(53%). Rf = 0.26 (25% ethyl acetate-hexanes).
1

H NMR (300 MHz, CDCl3): δ 8.40 (s, 1H), 7.99 (s, 2H), 7.67 (s, 1H), 6.49 (s, 1H), 5.00 (dd, J =

402.9, 6.4 Hz, 1H), 3.45 (s, 2H), 1.72 – 1.57 (m, 2H), 1.44 (s, 9H), 1.36 – 1.14 (m, 28H), 0.88 (t, J = 7.0 Hz,
3H).

4-((4-(Hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoic acid. Compound 2.27.

2.26
2.27
To compound 2.26 (1.19 g, 4.01 mmol), which was placed in a 50 mL round-bottom flask and chilled
in an ice bath, was added 15 mL of a 20 v/v% solution of trifluoroacetic acid in dichloromethane. After
one hour of stirring, starting material was no longer detected via TLC, and the solution was then
concentrated and dried under high vacuum. To the resulting residue was then added acetonitrile (40
mL), dry potassium carbonate (1.67 g, 12.0 mmol), and succinic anhydride (0.442 g, 4.42 mmol), and the
mixture was allowed to stir at room temperature. After 24 hours, 10% citric acid (50 mL) was added, and
the reaction was extracted with ethyl acetate (3 x 50 mL). The organic layers were then combined and
washed with saturated sodium chloride, dried with magnesium sulfate, filtered, and concentrated using
rotary evaporation. Column chromatography with gradient elution of 50–100% ethyl acetate/hexanes
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including 0.2% acetic acid gave product 2.27 as a light yellow solid (893 mg, 59% yield). Rf=0.36 (10%
methanol-dichloromethane).
1

H NMR (300 MHz, CD3OD): δ 8.45 (d, J = 1.7 Hz, 1H), 8.04 (dd, J = 8.1, 1.6 Hz, 1H), 7.68 (d, J = 8.1 Hz,

1H), 4.68 (s, 2H), 3.35 (t, J = 7.2 Hz, 2H), 2.64 – 2.50 (m, 4H), 1.67-1.51 (m, 2H), 1.44 – 1.24 (m, 6H), 0.89
(t, 6.6 Hz, 3H). 13C NMR (300 MHz, CD3OD) δ: 176.20, 175.10, 173.45, 149.33, 138.38, 135.85, 132.88,
131.05, 124.67, 74.12, 43.82, 41.22, 32.64, 30.29, 29.79, 27.74, 23.61, 14.36. HRMS-DART: [M-H]- calcd
for C18H25N3O6, 378.1671; found 378.1652.

1-Palmitoyl-2-(4-((4-(hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoyl)-sn-glycero-3phosphocholine (NB-PC). Compound 2.17.

2.27

2.17

In a six dram vial capped with a rubber septum, compound 2.27 (211 mg, 0.556 mmol) was
combined with dicyclohexylcarbodiimide (DCC, 0.86 mL, 0.556 mmol) and N,N-dimethylaminopyridine
(DMAP, 0.068 g, 0.556 mmol) in 4Å-molecular sieve-dried ethanol-free chloroform (2 mL) under argon,
along with crushed glass, similar to a method described by Rosseto and Hadju.90 After 30 min, palmitoyllysophosphatidylcholine (2.20, LPC, 69 mg, 0.138 mmol) was added in one portion and an argon
atmosphere was then reestabilished. After 6.5 hours of sonication, Dowex 50Wx8 residue was added
and the mixture was sonicated for 30 min before filtration through a fritted filter. After filtration and
concentration, normal phase column chromatography was carried out through elution with 15%
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methanol-dichloromethane containing 0.2% acetic acid to remove any unreacted acid, followed by
65:25:4 chloroform-methanol-water to remove the product. Residual water was removed by repeatedly
concentrating with acetonitrile. The solution was then concentrated to provide a slightly yellow lipid-like
substance 2.17 (65%). Rf = 0.32 (65:25:4 chloroform-methanol-water).
1

H NMR (500 MHz, 60% CDCl3-CD3OD) δ: 8.58 (s, 1H), 8.51 (s, 1H), 8.47 – 8.40 (m, 1H), 8.11 (d, J = 8.0

Hz, 1H,), 7.67 (d, J = 7.8 Hz, 1H), 5.27 – 5.20 (m, 1H), 4.73 (s, 2H), 4.36 (d, J = 11.3 Hz, 1H), 4.27 – 4.15 (m,
3H), 4.08 – 3.97 (m, 2H), 3.58 (s, 2H), 3.45 – 3.37 (m, 2H), 3.27 – 3.16 (m, 9H), 2.80 – 2.53 (m, 4H), 2.32
(t, J = 7.0 Hz, 2H), 1.63 (m, 4H), 1.43 – 1.22 (m, 30H), 0.95 – 0.85 (m, 6H). 13C NMR (500 MHz, 60% CDCl3CD3OD) δ: 174.45, 173.55, 172.81, 166.31, 148.43, 137.34, 135.37, 132.33, 130.35, 124.44, 71.53, 66.78,
64.23, 62.72, 59.48, 54.34, 41.16, 40.86, 34.34, 32.30, 31.93, 30.73, 30.68, 30.05, 30.02, 30.01, 29.99,
29.91, 29.87, 29.72, 29.66, 29.50, 27.11, 25.21, 22.94, 14.22. 31P NMR (500 MHz, 60% CDCl3-CD3OD) δ: 1.35, referenced to triphenyl phosphate at -17.70 ppm. AccuTOF DART-ESI: [M+Na]+ calcd for
C42H73N4O12P, 879.4866; found 879.4869. [α]22.5
+4.3° (c = 2.9, CHCl3).
𝐷

(S)-4-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane. Compound 2.49.

2.48

2.49

Sodium hydride (439 mg, 60%, in mineral oil, 12.2 mmol) in 40 mL dimethylformamide was
placed in a flame-dried 100 mL flask. To this was added compound 2.28 (1.00 mL, 8.10 mmol) in 20 mL
of dimethylformamide dropwise at 0° C. After one hour, para-methoxybenzyl chloride (1.65 mL, 12.2
mmol) was added. After stirring the reaction overnight, it was quenched with methanol. The reaction
was then diluted with 10 mL of water and extracted with dichloromethane (3 x 50 mL). It was then dried
with magnesium sulfate and filtered. After concentrating via rotary evaporation, the crude was purified
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with 25% ethyl acetate/hexanes to give a mixture of products. This crude 2.29 was concentrated and
used directly for the next reaction.
(R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol. Compound 2.30.

2.30
2.29
Crude compound 2.29 (2.08 g, 8.01 mmol based on prior step) was dissolved in 65 mL methanol
and para-toluenesulfonic acid (169 mg, 0.891 mmol) was added. After two days, sodium bicarbonate
(150 mg, 1.78 mmol) was added to quench the reaction, and the solution was concentrated with rotary
evaporation. Column chromatography with ethyl acetate then gave the product as a 1.41 g of clear oil
2.30 that solidified over time (83%, 2 steps). Characterization matched prior literature.91
1

H NMR (300 MHz, CDCl3) δ: 7.32 – 7.13 (m, 2H), 6.84 (d, J = 8.6 Hz, 2H), 4.42 (s, 2H), 3.84 (s, 2H),

3.75 (s, 3H), 3.68 – 3.48 (m, 3H), 3.48 – 3.38 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 159.25, 129.87, 129.43,
113.80, 73.05, 71.27, 70.87, 63.94, 55.20.
(S)-1-((tert-butyldiphenylsilyl)oxy)-3-((4-methoxybenzyl)oxy)propan-2-ol. Compound 2.31.

2.31
2.30
To compound 2.30 (127 mg, 0.600 mmol) dissolved in 10 mL anhydrous dimethylformamide was
added tert-butyldiphenylsilyl chloride (0.190 mL, 0.720 mmol) and imidazole (102 mg, 1.50 mmol). After
18 hours, the reaction solvent was removed, and the crude product was diluted with 15 mL of water,
and extracted with dichloromethane (3 x 20 mL). The crude was then dried with magnesium sulfate,
filtered, and concentrated via rotary evaporation. Column chromatography with 25–50% ethyl
acetate/hexanes gave the clear product 2.31 (45%). Characterization matched prior literature.91
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1

H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 7.4 Hz, 4H), 7.42 (t, J = 7.3 Hz, 2H), 7.40 – 7.33 (m, 4H),

7.21 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 2H), 4.46 (s, 2H), 3.90 (m, 1H), 3.78 (s, 3H), 3.71 (d, J = 5.4 Hz,
2H), 3.61 – 3.46 (m, 2H), 2.50 (d, J = 4.9 Hz, 1H), 1.05 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 159.11,
135.41, 133.09, 130.00, 129.64, 129.21, 127.61, 113.67, 72.93, 70.67, 64.67, 55.13, 26.72, 19.14.
Trans-2-Phenyl-1,3-dioxan-5-ol. Compound 2.41.

2.39

2.40

2.41
Compound 2.40 (10.3 g, 97.11 mmol, 1.3 eq) and compound 2.39 (12.2 g, 133 mmol) were
dissolved in 40 mL of dichloromethane and p-toluenesulfonic acid (2.53 g, 13.29 mmol) was added,
along with some 4Å molecular sieves. The reaction was refluxed for 16 hours. The reaction crude was
then filtered through Celite and extracted with 200 mL of a 1% potassium carbonate aqueous solution.
The aqueous portion was extracted (2 x 100 mL). The combined organic layer was dried with magnesium
sulfate and filtered. After concentrating, it was separated on normal phase column chromatography
using a 25-50% ethyl acetate/hexane gradient. Benzaldehyde eluted at 10% and a mixture of condensed
products eluted at 50%. The mixture of the cis and trans dioxane and dioxolane spots (four spots total)
were collected. Recrystallization from 1:1 petroleum ether/benzene, heating to 50° C and cooling to -20°
C, gave pure trans dioxane product 2.41 as a white solid after two rounds of recrystallization (12%).
Characterization matched previous literature.17, 92
1

H NMR (300 MHz, CDCl3) δ: 7.52 – 7.45 (m, 2H), 7.45 – 7.35 (m, 3H), 5.39 (s, 1H), 4.22 (dd, J =

11.1, 5.0 Hz, 2H), 3.94 – 3.78 (m, 1H), 3.52 (t, J = 10.0 Hz, 2H), 2.71 (d, J = 4.8 Hz, 0H). 13C NMR (75 MHz, )
δ: 137.34, 129.19, 128.42, 126.15, 100.98, 71.59, 61.10.
Octadecyl 4-methylbenzenesulfonate. Compound 2.42.
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2.50

2.42

Stearyl alcohol (2.50, 3.0 g, 11.19 mmol) was dissolved in 100 mL of dichloromethane.
Triethylamine (19.2 mL, 137.69 mmol) and para-toluenesulonyl chloride (3.30 g, 17.3 mmol) were
addied. The next day, 200 mL of 1 M hydrochloric acid was added, and this crude was extracted with
dichloromethane (2 x 100 mL). The combined organic layers were dried with magnesium sulfate,
filtered, and concentrated via rotary evaporation. Column chromatography with 10–25% ethyl
acetate/hexanes gave 3.8258 g of product 2.42 as a white solid (81%). Characterization matched a
similar procedure.93
1

H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 7.9 Hz, 2H), 7.34 (d, J = 7.6 Hz, 2H), 4.01 (t, J = 6.5 Hz,

2H), 2.45 (s, 3H), 1.68 – 1.54 (m, 2H), 1.23 (d, J = 11.9 Hz, 30H), 0.88 (s, 3H). 13C NMR (75 MHz, CDCl3) δ
212.76, 144.48, 129.65, 127.75, 70.59, 31.80, 29.57, 29.48, 29.38, 29.25, 28.80, 28.66, 25.18, 22.58,
21.53, 14.02.
5-(Octadecyloxy)-2-phenyl-1,3-dioxane. Compound 2.43.

2.42

2.41

2.43
To compound 2.41 (100 mg, 0.555 mmol) was added 60 mL of toluene, compound 2.42 (589 mg,
1.39 mmol), and potassium hydroxide (150 mg, 1.67 mmol). The reaction was heated to 100 °C
overnight. It was then heated to 125° C for 9 more hours and then cooled to room temperature. The
filtrate was poured through Celite and then concentrated. The organic layer was then diluted with 100
mL diethyl ether and was washed (2 x 50 mL) with saturated sodium chloride solution. Then the organic
layer was dried with magnesium sulfate, filtered, and concentrated. Column chromatography with 10%
ethyl acetate/hexanes gave 122 mg of product 2.43 as a white solid (51%).
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1

H NMR (300 MHz, CDCl3) δ: 7.63 – 7.44 (m, 2H), 7.43 – 7.27 (m, 3H), 5.54 (s, 1H), 4.33 (d, J = 13.9 Hz, 2H),

4.04 (d, J = 12.4 Hz, 2H), 3.54 (t, J = 6.8 Hz, 2H), 3.34 – 3.18 (m, 1H), 1.77 – 1.55 (m, 2H), 1.43 – 1.17 (m, 30H), 0.89
13

(s, 3H). C NMR (75 MHz, CDCl3) δ: 138.16, 128.81, 128.13, 126.19, 101.31, 70.58, 69.05, 68.99, 31.94, 29.80,
29.72, 29.70, 29.67, 29.64, 29.50, 29.38, 26.14, 22.71, 14.14,

2-(octadecyloxy)propane-1,3-diol. Compound 2.52.

2.52
2.51
To compound 2.51 (89.7 mg, 0.207 mmol) was added 2 drops of concentrated hydrochloric acid
in 10 mL of methanol. After reaction overnight, the solvent was concentrated under vacuum and the
residue was diluted with 10 mL water and extracted (3 x 10 mL) with diethyl ether. The combined
organic layer was dried with magnesium sulfate, filtered and concentrated using a rotary evaporator.
Column chromatography with 50–100% ethyl acetate/hexanes eluted the product, which was found by
staining TLC plates with phosphomolybdic acid. After concentrating and drying the relevant fractions
under vacuum, 60.8 mg of the white solid product 2.52 was collected (85%).

1

H NMR (300 MHz, CDCl3) δ: 3.77 (dd, J = 11.6, 4.5 Hz, 2H), 3.68 (dd, J = 11.6, 4.9 Hz, 2H), 3.57 (t,

J = 6.7 Hz, 2H), 3.46 (p, J = 4.7 Hz, 1H), 2.17 (s, 2H), 1.60 (p, J = 6.8 Hz, 2H), 1.40 – 1.15 (m, 30H), 0.88 (t, J
= 6.4 Hz, 3H).13C NMR (75 MHz, CDCl3) δ: 78.62, 69.34, 61.26, 31.08, 29.19, 28.86, 28.84, 28.82, 28.78,
28.75, 28.63, 28.53, 25.26, 21.86, 13.30.

2.8 Fluorescence-Based Irradiation Kinetics Assay of NB-PC
Stock solutions were initiated by weighing out samples of DOPC, DOPE, cholesterol, DSPE-PEG2000
amine, and/or NB-PC along with Nile red in vials. To the appropriate lipid components corresponding to
each liposome sample was added 500 μL of ethanol-free chloroform , and after brief vortexing, proper
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volumes of each lipid were pipetted into a clean vial per calculations on a 5 mM, 500μL total lipid scale,
to obtain the desired molar percentage of each component. Next, a solution of Nile red was added per
calculations on a 250 μM, 500 μL scale.

As an example, for liposomes comprised of 50% NB-PC and 50% DOPE, 500 μL of ethanol-free
chloroform were added to separate vials containing 4.9 mg NB-PC, 3.6 mg DOPE, and 4.2 mg Nile red,
producing stock solutions of 11, 9.7, and 26 mM concentrations, respectively. After 30 seconds of
vortexing, 109.4 μL of NB-PC, 129.2 μL of DOPE, and 4.74 μL of Nile red stock solutions were combined
in a new vial. The chloroform was dried with a nitrogen stream, and the lipids were subsequently dried
overnight under vacuum. The next day, the lipids were hydrated with 500 μL of MilliQ purified water,
vortexed, and incubated on a rotary evaporator at 60 °C for 3 sets of 20 min, with vortexing after each
set. Liposomes were frozen in a -40° C dry ice bath and then transferred to a 60° C water bath for 10
cycles and extruded through a 200 nm membrane for 21 passes using a LiposoFast extruder (Avestin,
Inc.), placing the uniform-sized vesicles into a fresh vial. DLS scans were performed to confirm the
formation of stable liposomes.

Next, 70 μL of this liposomal solution was diluted to 7 mL with ultrapure water. Two identical
samples were made by placing 3 mL of this dilute solution into quartz cuvettes and were sealed with
parafilm to minimize atmospheric exposure. After an initial fluorescence scan (λex = 595 nm; λem = 612
nm), one sample was irradiated with 350 nm light while suspended and covered by Pyrex beakers
between four 350 nm bulbs in a Rayonet Preparative Type RS photoreactor. The other sample was
placed in a dark container. For each fluorescence scan (every 5 minutes), the sample was removed from
the reactor or dark container and placed in the fluorimeter for scanning. Total amounts of time plotted
for release experiments represent the amount of time the sample spent in the photoreactor.
Experiments were run at least four times each, including runs with different batches of liposomes, and
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averaged to obtain the results shown in Figures 2.1 to 2.5, with error bars included to depict standard
error. Data were then curve fit using an exponential decay equation in SigmaPlot to obtain the values
shown

in

Tables

2.1-2.5,

according

to
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Equation

2.1

and

Equation

2.2.
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Spectra 2.1: 1H NMR. Compound 2.23. 4-((2,2,2-trifluoroacetamido)methyl)benzoic acid
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Spectra 2.2: 13C NMR. Compound 2.23. 4-((2,2,2-trifluoroacetamido)methyl)benzoic acid
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Spectra 2.3: 1H NMR. Compound 2.24. 3-Nitro-4-((2,2,2-trifluoroacetamido)methyl)benzoic acid
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Spectra 2.4: 13C NMR. Compound 2.24. 3-Nitro-4-((2,2,2-trifluoroacetamido)methyl)benzoic acid
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Spectra 2.5: 1H NMR. Compound 2.25. 4-(((tert-Butoxycarbonyl)amino)methyl)-3-nitrobenzoic acid
68

EtOAc
EtOAc
EtOAc

EtOAc
DMF
DMF

Spectra 2.6: 13C NMR. Compound 2.25. 4-(((tert-Butoxycarbonyl)amino)methyl)-3-nitrobenzoic acid
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Spectra 2.7: 1H NMR. Compound 2.26. 4-((4-(Hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoic acid
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Spectra 2.8: 13C NMR. Compound 2.26. 4-((4-(Hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoic acid
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Spectra 2.9: 1H NMR. Compound 2.47. 4-((4-(Dodecylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoic acid
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Spectra 2.10: 1H NMR. Compound 2.27. 4-((4-(Hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoic acid
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Spectra 2.11: 13C NMR. Compound 2.27. 4-((4-(Hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoic acid
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Spectra 2.12: 1H NMR. Compound 2.17. 1-Palmitoyl-2-(4-((4-(hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoyl)-sn-glycero-3phosphocholine (NB-PC)
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Spectra 2.13: 13C NMR. Compound 2.17. 1-Palmitoyl-2-(4-((4-(hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoyl)-sn-glycero-3phosphocholine (NB-PC)
76

Spectra 2.14: 31P NMR. Compound 2.17. 1-Palmitoyl-2-(4-((4-(hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoyl)-sn-glycero-3phosphocholine (NB-PC)
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Spectra 2.15: gCOSY NMR. Compound 2.17. 1-Palmitoyl-2-(4-((4-(hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoyl)-sn-glycero-3phosphocholine (NB-PC)
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Spectra 2.16: gHSQC NMR. Compound 2.17. 1-Palmitoyl-2-(4-((4-(hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoyl)-sn-glycero-3phosphocholine (NB-PC)
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Spectra 2.17: gHMBC. Compound 2.17. 1-Palmitoyl-2-(4-((4-(hexylcarbamoyl)-2-nitrobenzyl)amino)-4-oxobutanoyl)-sn-glycero-3phosphocholine (NB-PC)
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Spectra 2.18: 1H NMR. Compound 2.30. (R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol
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Spectra 2.19: 13C NMR. Compound 2.30. (R)-3-((4-methoxybenzyl)oxy)propane-1,2-diol
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Spectra 2.20: 1H NMR. Compound 2.31. (S)-1-((tert-Butyldiphenylsilyl)oxy)-3-((4-methoxybenzyl)oxy)propan-2-ol
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Spectra 2.21: 13C NMR. Compound 2.31. (S)-1-((tert-Butyldiphenylsilyl)oxy)-3-((4-methoxybenzyl)oxy)propan-2-ol
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Spectra 2.22: 1H NMR. Compound 2.41. trans-2-Phenyl-1,3-dioxan-5-ol
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Spectra 2.23: 13C NMR. Compound 2.41. trans-2-Phenyl-1,3-dioxan-5-ol
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Spectra 2.24: 1H NMR. Compound 2.42. Octadecyl 4-methylbenzenesulfonate
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Spectra 2.25: 13C NMR. Compound 2.42. Octadecyl 4-methylbenzenesulfonate
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Spectra 2.26: Compound 2.43. 5-(Octadecyloxy)-2-phenyl-1,3-dioxane
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Spectra 2.27: Compound 2.43. 5-(Octadecyloxy)-2-phenyl-1,3-dioxane
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Spectra 2.28: 1H NMR. Compound 2.44. 2-(Octadecyloxy)propane-1,3-diol
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Spectra 2.29: 1H NMR. Compound 2.44. 2-(Octadecyloxy)propane-1,3-diol
92

Spectra 2.30: Dynamic light scattering of NB-PC (Compound 2.17), kept in dark. Mean = 164.9 nm.
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Spectra 2.31: Dynamic light scattering of NB-PC (Compound 2.17) irradiated at 350 nm for 90 minutes. Mean = 186.3 nm.
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Chapter 3 : Phosphatidylcholine-Analog Lipid with a Nitrobiphenethyl Moiety within the sn-2 Fatty
Acid Chain for One and Two Photon Release
3.1 Introduction
The NB-PC lipid described in chapter 2 was designed with a one photon release in mind, as the
o-NB protecting group releases caged substrates within the 300 to 400 nm range.71, 73, 81a The efficiency,
however, of one-photon uncaging lies between 0.1 to 1% .94 The o-NB groups also do not have very
efficient releases, with most derivatives of 0.1 to 0.3 GM at the far end of the visible region or the near
end of the infrared region.95 The intensity of the laser must also be carefully controlled, because the
intensity required for obtaining a good release of o-NB groups can be powerful enough to cause cell
death above 7 mW. Damage occurs because the probability of excitation depends on the square of the
intensity used, and photobleaching is probable at high power.71, 95 For biological applications it is ideal to
have the wavelength of release in the visible or near infrared range. This will minimize damage to
proteins and nucleic acids with aromatic groups.
3.2 Two-Photon Excitation
An alternative to traditional absorbance irradiation is two-photon excitation (2PE), which has
many advantages. It utilizes infrared light, so it penetrates further into tissue, up to 1 mm as reported by
Svoda et al.,81c or up to 8 mm in bovine tissue.81c It also causes less scattering of light.71 Furthermore, it
can also be used on a femtoliter volume scale.81c TPA’s uncaging cross-section, which measures its
usefulness for release, has units of Goeppert-Mayer (GM), and it is the product of the cross sectional
area of the photon-absorbing portion of the molecule, δu, and the efficiency of substrates released per
photon, Φu ( 1 GM = 10-50 cm2/photon).71,

78-79

Compounds need to have at least 0.01 GM to be

considered for biological application, but at least 3 GM is desirable.79, 96
Two-photon excitation was first developed by Webb et al.97 One of the most important features
of this technique for chemical and biochemical applications is that only more biologically inert infrared
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light is used. The technique involves using excitation using two photons with twice the wavelength (half
light is used. The technique involves excitation using two photons with tice the wavelength (half the
energy) compared to the energy of an ultraviolet photon. The two photons must impact the same
chromophore on a small enough time scale to create an exited state. The absorbance is limited by the
properties of the chromophore itself. Additionally, due to its nonlinear nature in which the probability of
excitation depends on the square of the intensity of the laser beam, excitation can be localized to the
focal volume when using dual laser beams for absorbance.98 This also significantly lowers the probability
of photobleaching. The width of the focal volume will be directly proportional to the wavelength of
irradiation and inversely related to the numerical aperture of the lens.99
The method of improving φu is not completely understood yet, but δa seems to be generally
improved by extension of the conjugated system or by adding strong donor and acceptor moieties on
the opposite sides of the planar system.81a On the other hand, this is not always the case, as elongating
the nitrobenzyl system with a styrene substituent did not have an appreciable effect on the cross action
section. 100
3.3 Two Photon-Driven Release
A select few examples of two-photon release systems exist, but the field is still developing. One
of these examples is the protection of the 7-hydroxycoumrarin-3-carboxamide derivatives with the 1-(2nitrophenyl)ethyl cage, which has been reported at 0.6 GM at 740 nm (Figure 3.1).95 More recently, the
3-(2-propyl)-4’-tris-ethoxy(methoxy)-4-nitrophenyl (PEMB, 3.1) protecting group was used with a
fluorophore, having an uncaging cross-section of 3.7 GM at 740 nm.95 The producers of this cage, the
Goueldner group, also later also synthesized a 3-2-(propyl-1-ol)-4’-methoxy-4-nitrobiphenyl cage
(EANBP, 3.2), exhibiting 11 GM at 800 nm.98b
In another published paper, Buhler et al.,101 envisioning the potential for microelectronics and
DNA analysis, synthesized a number of 2-(2-nitrophenyl)propoxy)carbonyl (NPPOC) derivatives (3.3) and
96

3.1

3.2

3.3

3.4

3.8
3.6
3.7
3.5
Figure 3.1: Different caging groups with extended π systems
Compounds 3.1 to 3.3 are different forms of nitrobiphenethyl (NBP) systems. Compound 3.4 is a styryl
coumarin derivative with a high cross-section. Compound 3.5 eliminates the leaving group by
cyclizing. Additionally are nitrobenzofuran (3.6) and coumarin derivatives (3.7 and 3.8)
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used them to release thymidine under laboratory conditions. It was discovered that the substituents
exhibited a broad effect on the photocleavage rate.

Additionally, Gagey et al. used an o-

hydroxycinnamic chromophore (3.5) in zebrafish, having 1 to 10 GM at 750 nm.102
Lusic et al.103 redeveloped a new synthesis from the 3-nitro-2-ethyldebenzofuran (3.6), originally
developed by Momotake et al.,104 and found that this group releases its substrate at 0.6 GM at 710 nm.
A couple of coumarin derivatives have also been used, including the brominated 7-hydroxycoumarin-4ylmethyl (Bhc, 3.7)105 and the 8-bromo-7-hydroxyquinolone (BHQ, 3.8).106 These cages have two-photon
cross section values at 0.72 GM and 0.59 GM at 740 nm. Another extension of the coumarin system
utilized a styryl-conjugated derivative (3.4), which claims a two-photon cross section of 309 GM, by far
the highest cross-section known.107
3.4 Comparison of the o-Nitrobenzyl and Nitrophenethyl
The nitrobenzyl and the nitrophenethyl (3.1 to 3.3 in Figure 3.1) both have similar mechanisms
of photocleavage (Figure 3.2). After irradiation of the original molecule (3.9, 3.17), both compounds are
placed into the excited state. This occurs at the weakest bond in the molecule, the N-O π bond (3.10,
3.18). The benzyl hydrogen is then abstracted via a six-membered ring transition state (3.11, 3.19).
These structures are in resonance with the E-nitronic form (3.12, 3.20). For the o-NB system, proton
transfer then produces the aci-nitro intermediate (3.13), then reprotonation occurs to the Z-nitronic
form (3.14). With the o-NB system from the previous lipid NB-PC, discussed in chapter 2, the anionic
species will cyclize into a five membered ring (3.15), simultaneously reestablishing aromaticity.
Deprotonation and breakage of the ring forms the nitroso byproduct (3.16) and cleaves a bond at the
benzylic position. The nitrobiphenethyl from the current lipid NBP-PC, however, does not have the
leaving group at the benzylic position, but instead has an extra methylene. Instead of the fivemembered ring, it undergoes elimination, reestablishing aromaticity and releasing the leaving group to
3.21.
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NB-PC:

3.9

3.10

3.11

3.12

3.14

3.15

3.16

3.13

NBP-PC:

3.17

3.18

3.19
3.20
Figure 3.2: Comparison of NB-PC and NBP-PC systems

3.21

For the 2-nitrobenzyl (NB) system, excitation of 3.9 leads to 3.10. Structure 3.11 is in resonance with
E-nitronic acid 3.12. This then deprotonates to 3.13 and reprotonates to form Z-nitronic acid 3.14.
Cyclization then occurs to 3.15, and nitroso product 3.16 forms. On the other hand, for the
nitrobiphenethyl (NBP) system, the steps are parallel from the excitation of 3.17 to 3.18, abstraction
to 3.19, and resonance to 3.20. Instead of proton transfer, aromaticity is reestablished and the leaving
group, X, is expelled by forming a double bond.
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3.5 Discussion of Synthesis of NBP-PC
Because the original lipid NB-PC was useful for photochemical release in the ultraviolet region,
and not in the biologically friendly infrared region, we then sought to develop a photocleavable lipid for
this purpose with a nitrophenethyl chromophore and a push-pull system containing nitro and methoxy
groups at opposite ends. The synthesis (Figure 3.3) began with commercially available 4-ethylaniline
(3.22) and followed the procedures of other similar papers.101, 108 Acidic nitration first protonates the
aniline so that it becomes an electron-withdrawing group and then meta-direction reinforces the ethyl
group to direct nitration to the position ortho to the ethyl position (3.23). Leaving the product in the
protonated ammonium state gave the molecule more solubility for the following Sandmeyer reaction,
performed in aqueous solution. After the iodide (3.24) was produced, hydroxymethylation with catalytic
potassium tert-butoxide and paraformaldehyde gave the best yields for the production of 3.25. Other
methods attempted were Triton B with paraformaldehyde or aqueous formaldehyde with potassium
hydroxide.
Now that the triggerable nitrophenethyl handle was built, it was time to extend to system in
order to enhance δa. Thus the Suzuki reaction was employed to conjugate the aryl halide (3.25) with an
aromatic boronic acid (3.26) containing an electron-donating methoxy group, producing 3.27. To give
the fatty acid chain some flexibility and further hydrophobicity, 4-aminobutyric acid was conjugated to
the terminal hydroxy group of the nitrobiphenethyl system utilizing carbonyl diimidazole chemistry to
form 3.28. The LPC itself was attached in the same manner as NB-PC, by using carbodiimide coupling
under Steglich conditions to produce 3.29, or NBP-PC.
A different synthetic route was also attempted, starting the with commercially available 5amino-2-nitrobenzoic acid. Trouble with recrystallization, however, made this synthetic route less facile.
The finished product might still be interesting for synthesis, since the substitution of the final product
would be different, with the nitro group on the opposite side of the biphenyl system instead of the
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3.22

3.24

3.23

3.26

3.27

3.25

3.28
3.29
Figure 3.3: Synthetic scheme of NBP-PC.

Compound 3.22 was nitrated to form the sulfuric salt 3.23. A sandmeyer reaction then produced 3.24.
Hydroxymethylation from the acidic benzyl position led to 3.25. Coupling of the boronic acid 3.26
resulted in product 3.27. Coupling with carbonyldiimidazole, followed by 4-aminobutyric acid
produced 3.28. Ester coupling then resulted in final compound 3.29 (NBP-PC).
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carboxamide-attached linker.
Liposomes were then formed from the synthesized NBP-PC lipids. The kinetic studies were also
carried out under the same conditions as NB-PC. Briefly, to a vial was aliquoted NBP-PC in chloroform,
based on a 5 mM, 500 μL basis. Nile red was also added based on a 250 μM basis. After drying the
solution, the lipids were suspended in water with vortexing to form liposomes. Incubation above the Tc,
freeze-thaw cycles, and extrusion were carried out to produce uniform 200 nm unilamellar vesicles.
Liposome solutions were then diluted and transferred to a cuvette. The sample was then irradiated at
different intervals under UV irradiation, followed by reading the fluorescence of the sample. The same
experiment was performed with DOPC instead as a control. Dynamic light scattering spectra were also
taken of samples of 100% NBP-PC both kept in the dark and irradiated at 350 nm for 90 minutes.
Minimal size change was seen in the distribution, which could just infer that the action of
photodisruption was not fast enough to effect a change in liposome size.
The results of the photo-kinetics study showed faster and more extensive release than NB-PC.
The release of Nile red from the 100% NBP-PC sample plateaued in about five minutes rather than 30
minutes for NB-PC (Figure 3.4, Table 3.1). The 100% DOPC control sample, on the other hand, did not
appreciably release at all. What is also interesting is that the passive leakage of Nile red is additionally
reduced in the dark for NBP-PC samples over DOPC samples. This may be explained by the π stacking of
the NBP planar system with aromatic system of Nile red itself. The Tc will need to be measured to
determine stability relative to natural lipid formulation, since it is possible that the biphenyl system
stability does not have a Tc, due to its resistance to passive leakage. Since this sample is a significant
improvement over the NB-PC, it is a good candidate for two-photon irradiation studies, with a fastpulsed infrared laser as the irradiation source. The flux must be significantly high for photocleavage to
occur. Studies are currently underway to optimize the conditions for infrared release of this system.
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Figure 3.4: Irradiation of 100% NBP-PC, NB-PC, and DOPC, along with corresponding dark controls.
The NBP-PC exhibits more extensive and faster release with UV irradiation than NB-PC. Additionally, it
also demonstrates a decreased leakage of Nile red in the dark.

Table 3.1: Irradiation and control for 100% NBP-PC, NB-PC, and DOPC.
Data was tabulated from Figure 3.4 according to Equation 2.1 and Equation 2.2

UV
UV
UV
dark
dark
dark

%NBP-PC

%NB-PC

%DOPC

yo

A

k (min-1)

k (s-1)

R2

t1/2 (min)

100
0
0
100
0
0

0
100
0
0
100
0

0
0
100
0
0
100

0.0892
0.2032
0.8433
0.9749
0.8062
0.846

0.7377
0.8863
0.1477
0.0235
0.1872
0.1408

4.81E-01
5.03E-02
9.46E-02
1.99E+00
2.86E-02
4.83E-02

8.02E-03
8.38E-04
1.58E-03
3.32E-02
4.77E-04
8.05E-04

0.9338
0.9625
0.4232
0.4189
0.8595
0.3828

1.44
13.8
7.33
0.347
24.2
14.3
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3.6 Materials and Methods
Reagents and solvents were generally purchased from Acros, Aldrich, or Fisher Scientific and
used as received. Palmitoyl-lysophosphatidylcholine was purchased from Avanti Polar Lipids, Inc.
(Ablabster, AL) and 4-ethylaniline was purchased from Fisher Scientific. Dry solvents were obtained from
a Pure Solv solvent delivery system purchased from Innovative Technology, Inc. Column
chromatography was performed using 230-400 mesh silica gel purchased from Sorbent Technologies.
NMR spectra were obtained using a Varian Mercury 300 MHz, Varian 500, or Varian 600 MHz
spectrometer. Mass spectra were obtained with a JEOL AccuTof DART or a JEOL AccuTOF ESI
spectrometer with high-resolution capabilities. Optical rotations were measured with a Perkin-Elmer
241 Polarimeter using the sodium D line. Ultrapure water was purified via a Millipore water system (≥ 18
MΩ·cm) triple water purification system. Detection of Nile red emission decreases attributed to release
were performed using a Perkin Elmer LS55 fluorescence spectrometer. Samples were irradiated with a
Rayonet Preparative Type RS photoreactor while suspended in a cuvette with Pyrex as a filter.
4-Ethyl-3-nitrobezeneammonium hydrogen sulfate. Compound 3.23.

3.22

3.23
In a 50 mL round-bottom flask, commercially available 4-ethylaniline (3.22, 5.11 g, 42.2 mmol)
was slowly dissolved in 22 mL of concentrated sulfuric acid and chilled to 0°C. Next, 6 mL of
concentrated nitric acid was carefully added dropwise to the solution, minimizing smoke produced.
After two hours the mixture was poured over crushed ice and the orange solid was filtered through a
Büchner funnel lined with two pieces of filter paper. The filter cake was washed with small amounts of
ice cold water, and then traces of water were removed by coevaporation with several portions of
toluene (benzene was avoided due to toxicity issues). The resultant brown solid material (3.23, 10.1 g,
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91%) was carried to the next step as the hydrogen sulfate salt, according to a similar literature
precedent.108a
1

H NMR (500 MHz, DMSO-d6) δ: 8.10 (s, 3H), 7.56 (d, J=2.2 Hz, 1H), 7.43 (d, J=8.3 Hz, 1H), 7.29

(dd, J=8.3, 2.3 Hz, 1H), 2.75 (q, J=7.5 Hz, 2H), 2.17 (t, J=7.5 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ:
149.07, 138.24, 132.26, 131.96, 124.24, 114.39, 24.73, 15.00.
1-Ethyl-4-iodo-2-nitrobenzene. Compound 3.24.

3.24
3.23
The ammonium salt from the previous reaction (3.23, 10.11 g, 38.3 mmol) was suspended in 170
mL of water and 20 mL of 50% hydrochloric acid (v/v), and the reaction was cooled to 0°C. After one
hour, sodium nitrite (3.53 g, 5.12 mmol, in 16 mL of water) was added dropwise to the reaction, still at
0°C. After one more hour, 11.1 g of potassium iodide (11.1 g, 66.9 mmol) in a solution of 60 mL of
saturated sodium acetate was added, upon which vigorous bubbling occurred due to evolution of
nitrogen and orange smoke. The reaction was then allowed to stir overnight. It was then washed with
250 mL of 1M hydrochloric acid. The aqueous portion was extracted with ethyl acetate (3 x 150 mL). The
organic layer was then washed with 100 mL of a 20% w/v solution of sodium thiosulfate to reduce the
free iodide in solution. This was evident by the aqueous layer turning clear to yellow. The organic layer
was then dried with magnesium sulfate and filtered. After concentration, column chromatography with
5–10% ethyl acetate/hexanes gave 4.40 g of pure product (3.24, 69%) as a red oil that solidified upon
standing. NMR data for the product matched previous literature.101
1

H NMR (300 MHz, CDCl3) δ: 8.16 (s, 1H), 7.82 (d, J = 8.2 Hz, 1H), 7.12 (d, J = 8.2 Hz, 3H), 2.85 (q, J

= 7.5 Hz, 7H), 1.26 (t, J = 7.5 Hz, 6H).13C NMR (75 MHz, CDCl3): δ 13C NMR (75 MHz, CDCl3) δ 149.60,
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141.80, 138.55, 132.98, 132.80, 89.88, 25.91, 14.77. HRMS-DART: [M+H]+, calcd for C8H8NO2I, 277.9673;
found 277.96634.
2-(4-Iodo-2-nitrophenyl)propan-1-ol. Compound 3.25.

3.24

3.25
Compound 3.24 (687 mg, 2.67 mmol) was dissolved in 10 mL of 4 Å sieve-dried
dimethylsulfoxide. After 15 minutes, potassium tert-butoxide (42 mg, 0.374 mmol) was added in 1 mL of
tert-butanol. The solution turned a dark purple upon addition. After 30 minutes, the solution was heated
to 80°C, and after 30 minutes more, paraformaldehyde (81.0 mg, 2.67 mmol) was added, and the
reaction was allowed to reflux overnight. One equivalent more of tert-butoxide and paraformaldehyde
was added the next day when TLC confirms only starting material was present, and the reaction was
allowed to reflux until the next morning, at which time no starting material was detected by TLC. The
reaction was acidified with a saturated ammonium chloride solution until a pH of 3 or less was achieved.
The crude material was then extracted with ethyl acetate (3 x 50 mL), and the combined organic layers
were washed with 50 mL of saturated sodium chloride. After column chromatography with 25% ethyl
acetate/hexanes, the product 3.25 was collected as red oil (562 mg, 68%). NMR data matched previous
literature.101
1

H NMR (300 MHz, CDCl3) δ: 8.05 (s, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 3.85 –

3.66 (m, 2H), 3.46 (h, J = 6.6 Hz, 1H), 1.82 (s, 1H), 1.30 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ:
150.98, 141.48, 137.81, 132.51, 129.95, 90.44, 67.43, 36.15, 17.27) HRMS-DART [M+H]+, calcd for
C9H10NO3I, 307.97781; found 307.97808.
4-ethyl-4'-methoxy-3-nitro-1,1'-biphenyl-2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propan-1-ol.
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3.25
3.26
Compound 3.25 (521 mg, 1.92 mmol, 1 eq) was dissolved in 3 mL of 1,2-dimethoxyethane. Then
4-methoxyphenylboronic acid (442 mg, 2.00 mmol, 1.1 eq) and tetrakis(triphenylphosphorous)
palladium (50 mg, 0.0433 mmol, 0.03 eq) were added and the solution was stirred for 10 minutes at
room temperature. Next 1.46 g sodium carbonate and 7 mL water were added, and the reaction was
stirred under reflux until the reaction was complete, as determined by TLC. It was then filtered through
Celite with ethyl acetate and concentrated. Column chromatography with 10–25% ethyl
acetate/hexanes gave 436 mg of product 3.26 as red oil (89%). NMR characterization matched literature
precedent.101
1

H NMR (300 MHz, CDCl3) δ: 7.91 (s, 1H), 7.74 (dd, J = 8.2, 2.1 Hz, 1H), 7.52 (d, J = 8.8 Hz, 3H),

6.99 (d, J = 8.9 Hz, 2H), 3.86 (s, 3H), 3.81 (dd, J = 6.6, 3.8 Hz, 2H), 3.53 (q, J = 6.8 Hz, 1H), 1.86 (s, 1H),
1.35 (d, J = 6.9 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 159.82, 140.98, 140.14, 135.94, 130.58, 128.57,
128.05, 121.89, 120.12, 114.46, 111.03, 104.97, 67.85, 55.38, 36.14, 17.55. HRMS-DART [M+H]+, calcd
for C16H17NO4, 288.1230; found 288.1212.
2-(4'-Methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propyl 1H-imidazole-1-carboxylate. Compound 3.30.

3.22

3.30

107

Alcohol 3.26 (259 mg, 0.900 mmol) was dissolved in 4.5 mL of toluene, and carbonyldiimidazole
(175 mg, 1.08 mmol) and potassium carbonate (249 mg, 1.799 mmol) were added to the solution. After
2 hours, only partial conversion was evident by TLC. As a result, 100 mg more of carbonyldiimidazole
was added, and the next day, reaction showed conversion to the imidazole carbamate via both TLC and
AccuTOF-DART MS. The reaction was diluted between 50 mL ethyl acetate and 50 mL water, and ethyl
acetate was used to extract the solution (3 x 50 mL). The combined organic solution was dried with
sodium sulfate and the organic liquid decanted and concentrated and dried under vacuum. A crude
NMR of the red residue 3.30 was taken to confirm product form, and then it was used for the next
reaction. (286 mg, 83%)
1

H NMR (300 MHz, CDCl3): δ 8.07 (q, J = 1.1 Hz, 1H), 7.97 (t, J = 2.0 Hz, 1H), 7.83 – 7.73 (m, 1H),

7.70 (s, 1H), 7.59 – 7.48 (m, 3H), 7.41 – 7.32 (m, 1H), 7.12 (s, 1H), 7.07 – 6.98 (m, 3H), 4.59 (dd, J = 6.7,
1.1 Hz, 2H), 3.90 – 3.83 (m, 4H), 1.47 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 160.24, 150.48,
148.56, 141.17, 137.19, 133.92, 130.82, 130.50, 128.50, 128.23, 122.25, 117.21, 115.62, 114.72, 109.22,
103.91, 72.00, 55.54, 33.03, 17.79.
4-(((Benzyloxy)carbonyl)amino)butanoic acid. Compound 3.32.

3.31
3.32
Compound 3.31 (7.50 g, 75.0 mmol) was dissolved in 18 mL tetrahydrofuran, and
carboxybenzoyl chloride (CbzCl) was added (13.5 mL, 94.5 mmol). Afterwards, sodium hydroxide (6.04 g,
150 mmol) dissolved in 40 mL of water were cooled with an ice bath. Then 13.5 mL of carboxybenzoyl
chloride was added dropwise in 18 mL of THF to the reaction, and the reaction was allowed to warm to
room temperature overnight. The reaction was acidified with 1M hydrochloric acid, and the precipitate
was collected on a fritted filter. The material was dried from water with toluene, and then
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reconcentrated with methylene chloride. In all, 8.40 g of product 3.32 was collected as a white solid
(49%).101
1

H NMR (500 MHz, CDCl3) δ: 7.36 – 7.27 (m, 5H), 5.13 (d, J = 6.8 Hz, 1H), 5.08 (s, 2H), 3.26 – 3.18

(m, 2H), 2.35 (t, J = 7.3 Hz, 2H), 1.87 – 1.78 (m, 2H).13C NMR (126 MHz, CDCl3) δ: 178.22, 156.73, 136.44,
128.48, 128.10, 128.06, 66.75, 40.25, 31.15, 24.88.
tert-Butyl 4-(((benzyloxy)carbonyl)amino)butanoate. Compound 3.33.

3.32

3.33

Carboxylic acid 3.32 (1.782 g, 7.51 mmol) was added to a flame-dried 10 mL flask and dissolved
in 1.3 mL of toluene from a dry solvent system, added via syringe. Fresh, dry triethylamine from calcium
hydride was added (1.05 mL, 7.51 mmol), followed by 2,3,5-trichloroacetyl chloride (2.35 mL, 15.0
mmol). After 40 minutes, dimethylaminopyridine (1.84 g, 15.0 mmol) in 2.5 mL of tert-butanol was
added, and the solution turned yellow. The next day, the reaction was concentrated, and purification
was carried out with column chromatography using 25% ethyl acetate/hexanes to produce 3.33 as a
white solid. (1.54 g, 70%).101 NMR characterization matched the literature procedure.
1

H NMR (300 MHz, CDCl3): δ 7.39 – 7.24 (m, 5H), 5.08 (s, 3H), 3.21 (q, J = 6.7 Hz, 2H), 2.25 (t, J =

7.3 Hz, 2H), 1.77 (q, J = 7.1 Hz, 2H), 1.43 (d, J = 1.2 Hz, 9H). 13C NMR (126 MHz, CDCl3): δ: 172.64, 169.34,
156.48, 136.65, 128.52, 128.13, 128.09, 80.51, 66.62, 40.53, 32.84, 28.98, 28.11, 27.28, 25.24. HRMSDART [M+H]+, calcd for C16H23NO4, 294.1687; found 294.1687.
tert-Butyl 4-aminobutanoate. Compound 3.34.

3.33

3.34
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The fully protected 3.33 (825 mg, 2.81 mmol) was dissolved in 10 mL of methanol. 200 mg of
palladium on carbon was added, and the atmosphere was evacuated and a hydrogen atmosphere in its
place using a schlenk line and a hydrogen-filled balloon. After disappearance of starting material on TLC
and concentrating under vacuum, 424 mg of product 3.34 was obtained of the free amine (95%), and
the product matched the literature.101
1

H NMR (300 MHz, CDCl3): δ 4.34 (s, 2H), 2.81 (t, J = 6.9 Hz, 2H), 2.30 (t, J = 7.4 Hz, 2H), 1.82 (p, J

= 6.8 Hz, 2H), 1.44 (s, 9H).13C NMR (126 MHz, CDCl3) δ 172.55, 80.31, 40.60, 32.75, 28.07, 27.05.
tert-Butyl 4-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoate.
Compound 3.35.

3.30
3.35
Crude imidazole 3.30 (286 mg, 0.759 mmol), amine 3.34 (158 mg, 0.990 mmol), and
dimethylaminopyridine (27 mg, 0.2244 mmol) were stirred in 1.5 mL of THF. The next day, the reaction
was complete, as marked by disappearance of the starting material on TLC. After concentrating under
vacuum, the crude was purified using column chromatography with 30–35% ethyl acetate/hexanes. This
resulted in 228 mg of product 3.35 as a yellow solid (54% from 3.29)
1

H NMR (500 MHz, CDCl3) δ: 7.89 (d, J = 1.6 Hz, 1H), 7.73 (dd, J = 8.3, 2.1 Hz, 1H), 7.58 – 7.44 (m,

3H), 7.05 – 6.94 (m, 2H), 4.85 (t, J = 6.0 Hz, 1H), 4.26 (dd, J = 10.5, 6.0 Hz, 1H), 3.85 (d, J = 0.7 Hz, 3H),
3.77 – 3.63 (m, 1H), 3.16 (q, J = 6.7 Hz, 2H), 2.23 (t, J = 7.2 Hz, 2H), 1.75 (p, J = 7.1 Hz, 2H), 1.42 (d, J = 0.8
Hz, 9H), 1.36 (d, J = 7.3 Hz, 2H). 13C NMR (126 MHz, CD3OD): δ 170.05, 157.46, 153.67, 148.59, 137.80,
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132.79, 128.27, 127.93, 125.86, 125.58, 119.31, 112.04, 77.98, 66.22, 57.91, 50.95, 37.90, 25.56, 22.69,
18.10, 14.94. HRMS-DART [M+H]+, calcd for C25H32N2O7, 473.2282; found 473.2280.
4-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoic acid. Compound
3.28.

3.35

3.28

The tert-butyl ester 3.35 (139.4 mg, 0.2950 mmol) was dissolved in 3 mL of dichloromethane,
and 0.3 mL of trifluoroacetic acid was added. After three hours, 7.8 mL more of trifluoroacetic acid was
added. After 3 more hours, the reaction was marked as complete by TLC and concentrated. Column
chromatography with 10% methanol in dichloromethane gave 122 mg of product (99%).
1

H NMR (600 MHz, CD3OD): δ 7.91 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 9.2 Hz, 3H), 7.00 (d,

J = 8.8 Hz, 2H), 4.26 (dd, J = 10.6, 6.1 Hz, 1H), 4.17 (dd, J = 10.7, 7.7 Hz, 1H), 3.85 (s, 3H), 3.73 – 3.62 (m,
1H), 3.15 (t, J = 8.5 Hz, 1H), 2.32 (t, J = 7.4 Hz, 2H), 1.78 (p, J = 7.2 Hz, 2H), 1.37 (d, J = 7.1 Hz, 3H). 13C
NMR (75 MHz, CD3OD): δ: 175.78, 159.87, 156.91, 150.80, 140.24, 135.14, 130.62, 130.40, 128.51,
127.92, 121.55, 114.42, 68.54, 55.15, 39.94, 33.17, 31.06, 24.86, 17.34.. HRMS-DART [M+H]-, calcd for
C21H24N2O7, 415.1511; found 415.1525.
4-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoic acid. Compound
3.28.
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3.30

3.28

Compound 3.30 (318 mg, 1.11 mmol) was placed into a flame-dried flame with nitrogen
atmosphere. To this was added dry potassium carbonate (125 mg, 0.906 mmol), and then 5.5 mL of
toluene. Carbonyldiimidazole (175 mg, 1.08 mmol) was added in portions. An hour later, starting
material was unconverted, so 70 mg potassium carbonate and 50 mg carbonyldiimidazole were added.
After an hour 50 mg more carbonyldiimidazole was added. Finally, after one more hour, no more
starting material was evident. The solvent was concentrated, and dichloromethane was added and
subsequently concentrated. Next, 320 mg of potassium carbonate, 325 mg of 4-aminobutyric acid, and
3.2 mL of dry dimethylformamide were added. After 20 minutes, 46 mg of dimethylaminopyridine was
also added. After 2.5 hours, conversion was slight and detectable by mass spectrometry (AccuTOF
DART). The next day the intermediate was fully converted. The reaction was then acidified with 2 mL of
2M HCl and extracted with ethyl acetate (3 x 5 mL). Column chromatography with 100% ethyl acetate
afforded the product 3.28 (48%, 2 steps) as a yellow solid.
1

H NMR (600 MHz, CD3OD): δ 7.91 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.54 (d, J = 9.2 Hz, 3H), 7.00 (d,

J = 8.8 Hz, 2H), 4.26 (dd, J = 10.6, 6.1 Hz, 1H), 4.17 (dd, J = 10.7, 7.7 Hz, 1H), 3.85 (s, 3H), 3.73 – 3.62 (m,
1H), 3.15 (t, J = 8.5 Hz, 1H), 2.32 (t, J = 7.4 Hz, 2H), 1.78 (p, J = 7.2 Hz, 2H), 1.37 (d, J = 7.1 Hz, 3H). 13C
NMR (75 MHz, CD3OD): δ: 175.78, 159.87, 156.91, 150.80, 140.24, 135.14, 130.62, 130.40, 128.51,
127.92, 121.55, 114.42, 68.54, 55.15, 39.94, 33.17, 31.06, 24.86, 17.34.. HRMS-DART [M+H]-, calcd for
C21H24N2O7, 415.1511; found 415.1525.
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1-Palmitoyl-2-(-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoyl)-snglycero-3-phosphocholine (NBP-PC). Compound 3.37.

3.36
3.37
Compound 3.36 (169 mg, 0.415 mmol) and LPC (46 mg, 0.13 mmol) were coevaporated from
toluene several times and dried under vacuum. To this was added 6 mL chloroform freshly distilled from
phosphorous pentoxide, dicyclohexylcarbodiimide (92 mg, 0.419 mmol) and dimethylaminopyridine (54
mg, 0.461 mmol) were added. After 2 days of stirring, the reaction finally showed no lysophosphatidylcholine (LPC) by TLC. Dowex 80Wx8 was added and stirred for 30 minutes, after which the
reaction was cooled to 0° C and filtered through a Büchner funnel lined with filter paper and then
concentrated under vacuum. Column chromatography on a two inch skinny column with 15% methanol
in dichloromethane to remove excess fatty acid 3.36, and then 65:25:4 chloroform/methanol/water
gave the product 3.37 as a yellow oil or crystals (48.5 mg, 58% yield).
1

H NMR (500 MHz, 40% CD3OD -CDCl3) δ: 7.88 (s, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.55 – 7.46 (m,

3H), 6.98 (d, J = 8.3 Hz, 2H), 5.75 (s, 1H), 5.18 (s, 1H), 4.38 – 4.32 (m, 1H), 4.26 – 4.19 (m, 1H), 4.15 – 4.08
(m, 2H), 3.99 – 3.89 (m, 2H), 3.84 (s, 3H), 3.79 – 3.72 (m, 2H), 3.68 – 3.61 (m, 2H), 3.31 (s, 10H), 3.04 –
2.97 (m, 1H), 2.39 – 2.28 (m, 2H), 2.24 (t, J = 7.9 Hz, 2H), 1.76 (s, 2H), 1.54 (s, 2H), 1.34 (d, J = 7.0 Hz, 3H),
1.28 – 1.20 (m, 24H), 1.14 (t, J = 5.6 Hz, 2H), 0.87 (q, J = 7.3 Hz, 3H). 13C (500 MHz, 40% CD3OD -CHCl3) δ:
173.60, 172.79, 159.92, 156.44, 150.80, 140.23, 135.23, 130.60, 130.48, 128.60, 128.39, 128.02, 127.59,
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121.70, 114.52, 66.32, 62.68, 59.33, 55.35, 54.36, 40.03, 34.01, 33.28, 33.20, 31.91, 29.71, 29.68, 29.67,
29.65, 29.55, 29.35, 29.33, 29.17, 29.15, 24.83, 22.67, 17.67, 14.11. 31P NMR (121 MHz, 40% CD3OD +
CHCl3): -0.44. Rotation: [𝛼]24
𝐷 = +1.5 (c 2.1). HRMS AccuTOF-ES:I [M+Na+1] calcd for C45H72N3O13P,

917.4740; found 917.4926.
3.7 Fluorescence-Based Irradiation Kinetics Assay of NBP-PC
Stock solutions were initiated by weighing out samples of DOPC, DOPE, cholesterol, DSPE-PEG2000
amine, and/or NBP-PC along with Nile red in vials. To the appropriate lipid components corresponding
to each liposome sample was added 500 μL of ethanol-free chloroform, and after brief vortexing, proper
volumes of each lipid were pipetted into a clean vial per calculations on a 5 mM, 500μL total lipid scale,
to obtain the desired molar percentage of each component. Next, a solution of Nile red was added per
calculations on a 250 μM, 500 μL scale.

As an example, for liposomes comprised of 100% NBP-PC, 500 μL of ethanol-free chloroform was
added to separate vials containing 6.8 mg NBP-PC and 3.9 mg Nile red, producing stock solutions of 15
and 25 mM concentrations, respectively. After brief vortexing, 164 μL of NBP-PC and 5.10 μL of Nile red
stock solutions were combined in a new vial. The chloroform was dried with a nitrogen stream, and the
lipids were subsequently dried overnight under vacuum together in a 500 mL round bottom flask. The
next day, the lipids were hydrated with 500 μL of MilliQ purified water, vortexed, and incubated on a
rotary evaporatory at 60 °C for 3 sets of 20 min, with vortexing after each set. Liposomes were then
freeze-dried between a -40° C dry ice bath and a 60° C water bath for 10 cycles and extruded through a
200 nm membrane for 21 passes using a LiposoFast extruder (Avestin, Inc.), placing the uniform-sized
vesicles into a fresh vial. DLS scans were performed to confirm the formation of stable liposomes.

Next, 70 μL of this liposomal solution was diluted to 7 mL with ultrapure water. Two identical
samples were made by placing 3 mL of this dilute solution into quartz cuvettes and were sealed with
114

parafilm to minimize atmospheric exposure. After an initial fluorescence scan (λex = 595 nm; λem = 612
nm), one sample was irradiated with 350 nm light while suspended and covered by Pyrex beakers
between four 350 nm bulbs in a Rayonet Preparative Type RS photoreactor. The other sample was
placed in a dark container. For each fluorescence scan, the sample was removed from the reactor or
dark container and placed in the fluorimeter for scanning. Total amounts of time plotted for release
experiments represent the amount of time the sample spent in the photoreactor. The fluorescence was
checked after the following total irradiation intervals: 0.5, 1, 1.5, 2, 3, 4, 5, 10, 15, 20, 25, 30, 60, and 90
minutes. Experiments were run at least four times each, including runs with different batches of
liposomes, and averaged to obtain the results shown in Figure 3.4 and Table 3.1 with error bars included
to depict standard error. Data were then curve fit using an exponential decay equation in SigmaPlot to
obtain the values shown in Tables 2.1-2.5, according to Equation 2.1 and Equation 2.2.

3.8 Conclusion
The nitrobiphenethyl group is an extended system that can be used for better release under UV
light over the nitrophenyl, due to the elongation of its pi system. As opposed to the NB-PC lipids, the
NBP-PC lipid releases Nile red about six times fast, with a more extensive release. Since it works very
well under UV light, it will be used in studies with two photon infrared light for more biocompatible
release. Overall, this is a tunable liposome release system that is biocompatible because of the high
degree

of

similarity

of

this
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lipid

to

natural

PC.
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Spectra 3.2: 13C NMR. Compound 3.23. 4-Ethyl-3-nitrobezeneammonium hydrogen sulfate
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Spectra 3.3: 1H NMR. Compound 3.24. 1-Ethyl-4-iodo-2-nitrobenzene
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Spectra 3.4: 13C NMR. Compound 3.24. 1-Ethyl-4-iodo-2-nitrobenzene
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Spectra 3.5: 1H NMR. Compound 3.25. 2-(4-Iodo-2-nitrophenyl)propan-1-ol
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Spectra 3.6: 13C NMR. Compound 3.25. 2-(4-Iodo-2-nitrophenyl)propan-1-ol
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Spectra 3.7. 1H NMR. Compound 3.26. 4-Ethyl-4'-methoxy-3-nitro-1,1'-biphenyl-2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propan-1-ol
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125

Spectra 3. 9: 1H NMR (crude). Compound 3.30. 2-(4'-Methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propyl 1H-imidazole-1-carboxylate
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Spectra 3.10: 13C NMR (crude). Compound 3.30. 2-(4'-Methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propyl 1H-imidazole-1-carboxylate
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THF

Spectra 3.11: 1H NMR. Compound 3.32. 4-(((Benzyloxy)carbonyl)amino)butanoic acid
128

13 NMR. Compound 3.32. 4-(((Benzyloxy)carbonyl)amino)butanoic acid
Specta 3.3.13.
12: 1H
Spectra
C NMR. Compound 3.32. 4-(((Benzyloxy)carbonyl)amino)butanoic acid
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Spectra 3.14. 1H NMR. Compound 3.33. tert-Butyl 4-(((benzyloxy)carbonyl)amino)butanoate
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Spectra 3.15: 13C NMR. Compound 3.33. tert-Butyl 4-(((benzyloxy)carbonyl)amino)butanoate
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Spectra 3.16: 1H NMR. Compound 3.34. tert-Butyl 4-aminobutanoate
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Spectra 3.17: 13C NMR. Compound 3.34. tert-Butyl 4-aminobutanoate
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EtOAc

EtOAc
EtOAc

Spectra 3. 18: 1H NMR. Compound 3.35. tert-Butyl 4-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoate
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EtOAc

EtOAc

Spectra 3.19: 13C NMR. Compound 3.35. tert-Butyl 4-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoate
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CH2Cl2
CDCl3

CD3OD

CD3OD

Spectra 3. 20: 1H NMR. Compound 3.28. 4-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoic acid
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CD3OD

Spectra 3.21: 13C NMR. Compound 3.28. 4-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoic acid
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Spectra 3.22: 1H NMR. Compound 3.37. 1-Palmitoyl-2-(-(((2-(4'-methoxy-3-nitro-[1,1'-biphenyl]-4-yl)propoxy)carbonyl)amino)butanoyl)-snglycero-3-phosphocholine (NBP-PC)
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Specta 3.28: Dynamic light scattering of 100% NBP-PC (Compound 3.37) without irradiation. Mean = 154.0 nm.
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Specta 3. 29: Dynamic light scattering of 100% NBP-PC (Compound 3.37) irradiated at 350 nm. Mean = 145.2 nm.
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Chapter 4 : Caging of Diacylglycerol Signaling with a 2-Nitrobenzyl Group
4.1 DAG and Its Role with PKC
Natural sn-1,2-diacylglycerol (DAG) is an important signaling lipid, consisting of a glycerol moiety
with two esterified tails and an overall S configuration at the sn-2 methine carbon. DAG is produced in
vivo by one of three ways. Most notably, it is produced by phospholipase C (PLC) hydrolysis of
phosphatidylcholine (PC), producing phosphorylcholine as a byproduct. Secondly, it can be produced
from the PLC hydrolysis of phosphoinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3).
Thirdly, it can be produced by phospholipase D (PLD) hydrolysis of PC to phosphatidic acid (PA), followed
by hydrolysis to DAG by phosphohydrolase.109
DAG is known for its role with the isoenzymes of protein kinase C. It binds either to a C1 domain
of novel PKCs with or without calcium or to the C2 domain of classical PKC isoenzymes with calcium and
phosphatidylserine (PS).8, 110 PKC has been found to participate in many roles, including cellular events
such as apoptosis, survival, proliferation, as well as the migration of organelles within the membrane.
PKC activity was originally discovered in response to an observation that phorbol esters, especially
tetradecanoyl phorbol acetate (TPA), acted as a tumor promoter for infected mice. It was then found
that DAG activates PKC in the presence of phosphatidylserine (PS). Also, it was found that DAG could
compete out phorbol esters in PKC binding, although over time the binding of DAG diminishes.8 Another
role for DAG includes the activation of acidic sphingomyelinase (SMase) to ceramide and the possible
reversal of ceramide-induced apoptosis.109 Furthermore, DAG also binds other proteins, such as DGKγ,
Munc13, and RasGRP.111
The photochemical protection of DAG may be useful for in situ quantification by biological
studies to characterize PKC activation and binding. The Walker group used a nitrobenzyl-protected DAG
to study the response of cardiac muscle to DAG, finding that it strengthened the contraction strength.112
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They also later used a coumarin-caged DAG for similar studies.113 The Schultz group also used
nitrobenzyl and coumarin versions of DAG with different acyl chains of different degrees of saturation,
lengths, and regiochemistry.114 Their studies with the C1 domain of a green fluorescent probe showed
that there is a preference for certain acyl compositions over others, and the binding is not solely
mediated by headgroup binding.
4.2 Discussion of NB-DAG Synthesis and Future Studies
The DAG we designed and synthesized was a nitrobenzyl version. The synthesis was completed
in three steps, starting with 2-nitrobenzyl bromide (Figure 4.1). The most limiting step is the first one,
which consists of making an ether bond from electron-deficient nitrobenzyl bromide (4.1) and (S)glycerol acetonide (4.2) to form 4.3. The best yield resulted from silver(I) oxide coupling, though similar
results could be obtained using phase transfer ammonium tetrabutylammonium salts. The biggest issue
with this reaction is that the typical reagent for ether bonds, sodium hydride, produces decomposition
products or polymerization reactions.80,

115

Yields can be slightly improved by using a nitrobenzyl

derivative with a better leaving group. After ether formation, acetal deprotection gave the free diol
(4.4), and finally Steglich coupling with stearic acid gave the nitrobenzyl-protected DAG (4.5, NB-DAG)
compound.
NMR spectroscopy has been used to visualize the spectra over time in response to irradiation
(Figure 4.3). There is a general decrease of the original aromatic and benzylic peaks, and an increase of
new peaks. Over time, more than one sn-3 peak is evident. This could be due to the 1,2 and 1,3-isomers
of DAG. Preliminary results demonstrate an exponential increase over approximately 30 minutes. Future
studies will focus on microplate characterization of PKC binding (Figure 4.2). Specifically, liposomes
containing DAG will be incorporated into liposomes and transferred to microplates with a buffer
containing phosphatidylserine (PS). PKC binding can be detected after irradiation in the microplate wells
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4.1

4.2
4.3

4.4

4.5
Figure 4.1: Synthesis of NB-DAG (Compound 4.5)
Ether formation between bromide 4.1 and alcohol 4.2 produces 4.3 with silver(I) oxide. Catalytic acid
produces 4.4. Fatty acid coupling forms the final product 4.5.

Figure 4.2: Photochemical activation of PKC after UV Irradiation.
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Time = 360 min

Time = 240 min

Time = 120 min

Time = 90 min

Time = 60 min

Time = 30 min

Time = 0 min

Figure 4.3: Irradiation of NB-DAG (Compound 4.5) over time (bottom to top) shows conversion of compound 4.5 to others compounds,
including DAG isomers.
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via a chemiluminescence assay according to a previous procedure116 or by .live cells with with GFPtagged PKCs.114
4.3 Materials and Methods
Reagents and solvents were generally purchased from Acros, Aldrich or Fisher Scientific and
used as received. Dry solvents were obtained from a Pure Solv solvent delivery system purchased from
Innovative Technology, Inc. Column chromatography was performed using 230-400 mesh silica gel
purchased from Sorbent Technologies. NMR spectra were obtained using a Varian Mercury 300 MHz or
Varian VNMRS 500 MHz spectrometer.
(S)-2,2-dimethyl-4-(((2-nitrobenzyl)oxy)methyl)-1,3-dioxolane. Compound 4.3.

4.1

4.2

4.3
In a 100 mL flask, commercially available (S)-glycerol acetonide (4.1, 0.10 mL, 0.810 mmol) was
dissolved in 10 mL of dichloromethane. To this was added crushed sodium hydroxide (486 mg, 12.2
mmol) in 50 mL of water to make a 10% w/v solution, followed by 2-nitrobenzyl bromide (385 mg, 2.02
mmol, 2.5 eq) and Tetrabutylammonium hydrogen sulfate (385 mg, 1.133 mmol, 1.4 eq). After three
days, the reaction was diluted with dichloromethane and extracted (3 x 10 mL) with the same organic
solvent. The organic layer was then washed with 10 mL of saturated sodium chloride and dried with
magnesium chloride and filtered. After concentration, the column was run with 15 to 25% ethyl acetate
in hexanes. A yellow solid mixture of the bromide and acetonide was collected. The product was 71% of
the collected material and was carried along, with the bromide, to the next reaction (17%). [NOTE: 2nitrobenzyl alcohol was also produced, in a 2:1 ration of product 4.3 to the alcohol.]
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1

H NMR (300 MHz, CDCl3) δ: 8.06 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 7.8 Hz, 1H), 7.65 (t, J = 8.1 Hz,

1H), 7.44 (t, J = 8.2, 6.7 Hz, 1H), 4.95 (s, 2H), 4.36 (p, J = 6.0 Hz, 1H), 4.10 (dd, J = 8.3, 6.5 Hz, 1H), 3.80
(dd, J = 8.3, 6.8 Hz, 1H), 3.67 (dd, J = 9.9, 5.6 Hz, 1H), 3.62 (dd, J = 9.9, 5.1 Hz, 3H), 1.44 (s, 3H), 1.38 (s,
3H). 13C (75 MHz, CDCl3) δ: 134.76, 133.58, 128.68, 128.00, 124.62, 109.52, 74.60, 72.09, 70.00, 66.59,
26.71, 23.36. HRMS-DART: [M]+ calcd for C13H17NO4, 268.11795; found 268.11612.
(R)-3-((2-nitrobenzyl)oxy)propane-1,2-diol. Compound 4.4.

4.4
4.3
Acetonide 4.3 (29.7 mg, 0.111 mmol) was dissolved in 1 mL of methanol and p-toluenesulfonic
acid (4.00 mg mg, 0.0245 mmol) was subsequently added. The reaction was stirred until completion as
determined by TLC, and then it was quenched with sodium bicarbonate (4.1 mg, 0.0490 mol). After
concentration, the crude was extracted (3 x 10 mL) with dichloromethane from 10 mL of water. The
organic layer was then washed with saturated sodium chloride and dried with magnesium chloride, then
filtered and concentrated via rotary evaporation. Column chromatography with 75%-100% ethyl
acetate/hexanes, produced 25.2 mg of the yellow oil 4.4 (47%).
1

H NMR (300 MHz, CDCl3) δ: 8.05 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 7.7 Hz, 1H), 7.65 (t, J = 7.5 Hz,

1H), 7.53 – 7.40 (m, 1H), 4.93 (s, 2H), 3.97 (s, 1H), 3.76 (d, J = 11.8 Hz, 1H), 3.73 – 3.61 (m, 3H), 2.83 (s,
1H), 2.39 (s, 1H). 13C NMR (75 MHz, CDCl3) δ: 134.18, 133.68, 128.78, 128.35, 124.78, 111.09, 72.50,
70.65, 70.14, 63.82.
(S)-3-((2-nitrobenzyl)oxy)propane-1,2-diyl distearate. Compound 4.5.
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4.4

4.5
Dimethylaminopyridine (DMAP, 418 mg, 3.423 mmol) and stearic acid acid (4.4, 974 mg, 3,42
mmol) were mixed together in chloroform. Then dicyclocarbodiimide (DCC, 0.31 mL, 2.04 mmol) was
added along with the diol 4.11, and the reaction was refluxed at 50° C for four hours. Next the reaction
was chilled in ice bath and filtered to remove urea, rinsing with cold dichloromethane, and the reaction
was concentrated under rotary evaporation. Column chromatography with 10-25% ethyl
acetate/hexane eluted product 4.5 (307 mg, 59%). Rf = 0.31 (10% ethyl acetate/hexanes).
1

H NMR (300 MHz, C6C6) δ 7.67 (dd, J = 8.2, 1.2 Hz, 1H), 7.53 (d, J = 7.9 Hz, 1H), 6.99 (td, J = 7.8,

1.1 Hz, 1H), 6.70 (t, J = 7.8 Hz, 1H), 5.44 (dt, J = 9.1, 5.1 Hz, 1H), 4.61 (d, J = 5.7 Hz, 2H), 4.45 (dd, J = 11.9,
3.6 Hz, 1H), 4.21 (dd, J = 11.9, 6.6 Hz, 1H), 3.43 – 3.25 (m, 2H), 2.23 (dt, J = 18.0, 7.4 Hz, 4H), 1.71 – 1.53
(m, 4H), 1.43 – 1.14 (m, 56H), 0.98 – 0.86 (m, 6H). 13C NMR (300 MHz, C6C6) δ 173.38, 172.95, 147.06,
134.61, 133.64, 128.42, 128.00, 124.65, 24.65, 69.67, 62.48, 31.91, 29.69, 29.67, 29.65, 29.47, 29.35,
29.28, 29.27, 22.67, 14.08.
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Chapter 5 : Azide-Alkyne Linkers and Light-Interacting Compounds
5.1 Cyclooctyne Lipid Conjugate for Copper-Free Presentation of Functional Handle
The synthesis of linkers for surface decoration of liposomes is an important concept for drug
delivery. Additionally, when a linker is attached to the exterior of the liposome, many factors affect
reactivity of a tag or handle attached by a linker, including composition of the linkers, type of chemistry
used to attach the tag or reactive handle to the linker, and length of the linker. If a linker is too short,
this may bury the reactive handle in the membrane. Conversely, a longer linker does not always
correspond to better reactivity. For example, Stefanick et al.117 found that tethering peptides on a
PEG2000 attachment to liposomes was much less effective than a PEG350 strand for cellular uptake. The
moiety used as the reactive handle is also important, because for in vivo studies, handles should be used
that are bio-orthogonal to normal biological processes.
The azide-alkyne cycloaddition is a reaction that is classified as click chemistry, which refers to
reactions with reactive units that quickly and efficiently react on different scales of reaction.118 The
azide-alkyne reaction was developed by Huisgen et al. in 1967,119 but the introduction of the coppercatalyzed azide-alkyne reaction gave this reaction much more utility, especially for biological systems. It
has been one of the forefront reactions of click chemistry decades afterwards. This copper-mediated
azide-alkyne reaction was an improvement to the heat-mediated azide-alkyne cycloaddition, which led
to a mixture of products with different regiochemistry.120 Other types of click chemistry include inverse
electron demand reactions such as the trans-cyclooctene-tetrazine reaction, the norborene-tetrazine
reaction, and the cyclobutene-tetrazine reaction.121 The copper-free cycloaddition was developed by the
Bertozzi group, and it has been used widely in aqueous systems. The ring strain of cyclooctynes or
cyclononynes provides enough strain to make the reaction proceed without requiring the copper
catalyst, which is toxic to living cells.121
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Various lipids with a PEG linker and a cyclic alkyne have been used. Feldborg et al. evaluated
different reactive handles in conjunction with the tumor-targeting peptide.122 One important finding was
that reaction of the surface of the liposome had a much bigger effect than reactivity in solution.
Presentation of an alkyne on the surface of the liposomes was about 1.5 times as effective as an azide
on the surface. Zhang et al.42 also used a system that involved a PEGylated lipid with a reactive
cyclyooctyne handle. They used copper-free cycloaddition to attach thrombomodulin onto to surface of
liposomes, leading to better protein C activation than with thrombomodulin alone.123 Jølck et al. utilized
an assay with PEGylated lipid conjugates containing terminal or cyclic alkynes that were efficiently
evaluated with a pro-fluorogenic azido-coumarin species to validate conjugation of an RGD peptide.124
The dibenzylcyclooctyne (DBCO) will be utilized as a copper-free lipid tether to azidefunctionalized moieties. In the current work, a PE-PEG2000-amine (5.3) conjugate was reacted with a
(DBCO) species, either donated from the Popik laboratory, or commercially purchased from Sigma
Aldrich (Figure 5.1). This reaction was either attempted by HATU and triethylamine or by first activating
the carboxylic acid (5.1) as the N-hydroxysuccinamide ester (5.2), then reacting of the activated ester
with the amine conjugate. Reaction was verified by TLC and staining with ninhydrin or a solution of a
coumarin azide compound125 at a 5 mM solution in dimethylsulfoxide. MALDI-MS also verified the
presence of product (5.4) via a shift of the mass-to-charge ratio. Purification was performed by size
exclusion chromatography and reverse phase chromatography. Normal phase chromatography was
found to be problematic because it absorbed most of the longer distributions of 5.4. The presence of
starting material was not detected by TLC, but the presence of reagents has not been ruled out, as the
NMR is complex and the presence of small ions cannot be verified in the presence of fragmentation of
the product via mass spectrometry techniques. Preliminary results have demonstrated that a profluorescence assay is also a good method of testing for successful cycloaddition with a coumarinazide,125 species, though further work will be performed to validate this result. The coumarin161

5.1

5.2

5.3

5.4
Figure 5.1: Synthesis of DBCO-PEG-PE
Acid 5.1 is activated to ester 5.2. This is reacted with amine 5.3 to produce cyclic alkyne lipid tether
5.4
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cycloalkyne mixture will be monitored over time as a dramatic increase in fluorescence. Further testing
will also be performed to characterize binding affinity using a microplate assay similar to the one used
by Bostic et al.,126 in which a biotin-alkyne linker was tethered on streptavidin-coated microplate wells
and liposomes containing PEGylated cyclyooctyne lipids were reacted at different concentrations.
5.2 Materials and Methods (DBCO-PEG-PE)
Dibenzyocyclooctyne-N-hydroxysuccinamide ester (DBCO-PEG-PE)

5.1
5.2
Compound 5.1 (3.1 mg, 9.3 μmol,) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC,
5.0 mg, 0.026 mmol) were weighed into a 1.5 mL eppendorf tube and dissolved in 0.75 mL of dry
dichloromethane. After 10 minutes, N-hydroxysuccinamide (8.9 mg, 0.077 mmol) was added. More 1ethyl-3-(3-dimethylaminopropyl)carbodiimide or N-hydroxysuccinamide were added as needed until the
starting material was consumed. This was determined by TLC monitoring of the reaction with ethyl
acetate as the solvent. An Rf value of 0.81 in ethyl acetate corresponded to the crude product, an Rf of
0.61 corresponded to the acid, and HOSu stayed at the baseline. After completion, the crude was diluted
with 5 mL dichloromethane, and then it was washed with water (2 x 5 mL), 2M hydrochloric acid (2 x 5
mL), and again with water (2 x 5 mL). This crude was concentrated and dried under vacuum for one
hour. The crude weight of 5.2 was 8.8 mg, and it was directly used for the next reaction.
Dibenzocyclooctyne-polyethylene glycol2000-phosphatidylethanolamine (DBCO-PEG-PE)

5.2

5.3

5.4
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Compound 5.3 (12.8 mg, 4.6 μmol) was weighed into an eppendorf tube. Compound 5.2 was
transferred with 0.6 mL dichloromethane in portions to the amine. Triethylamine (5 μL), freshly distilled
from calcium hydride, was added. After disappearance of the amine via visualization on TLC, the
dimethylformamide was distilled from the reaction. The crude was then separated via Sephadex G-50
size exclusion chromatography with 50% methanol-water. The fractions that were more highly visible
under 365 nm light when stained with azido coumarin were collected and co-evaporated with
acetonitrile to remove water. Then the crude was passed through a C8 reverse phase column to remove
the leached Sephadex. The fractions containing product were collected, co-evaporated with acetonitrile
and dried under vacuum.
1

H NMR (600 MHz, CDCl3): the NMR is more difficult to analyze, but the important areas are the

aromatic region between 6.5-8.0 ppm, the PEG2000 peak at 3.7 ppm, and the methyl peak at 0.9 ppm.
MALDI-TOF MS illustrates a shift from the amine 5.3 to the product 5.4.
5.3 Azide and Alkyne Lipids for Terminal Conjugation
Another alkyne-azide lipid project in the preliminary stages is the production of PC analogues
presenting an azide or alkyne on the terminal end, similar to phospholipids synthesized by O’Neil et al.127
or Lampkins et al.128 Initial attempts to produce a fatty acid with a terminal azide (5.6) were successful in
moderate yields, via 5.5. However, producing an alkynoic acid (5.9) has proved more difficult due to the
presence of the carboxylic acid. This can be related to the pKa trend, as hydrazoic acid has a pKa of about
4.7, a simple carboxylic acid is also about 4.7, and a terminal alkyne is approximately 26. Since basicity
parallels nucleophilicity in many cases, this can also be used to predict reactivity in this situation. Since
hydrazoic acid, the conjugate acid of sodium azide, has a similar pKa with carboxylic acids, the reaction
can be favored by an excess of sodium azide. On the other hand, deprotonation of the carboxylic acid is
favored by the acetylide anion by more than a factor of five, so nucleophilic addition competes heavily
with acid-base chemistry. In fact, the alkyne is readily made with a long chain alkyl bromide, without the
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presence of the carboxylic acid. Therefore to remedy this situation, iodo acids have also been
synthesized (Figure 5.2), in order to give a compound with a better leaving group. Then conjugation to
commercially available LPC will be more favorable.
5.4 Methods and Materials (Alkyne and Azide Lipids)
6-Iodohexanoic acid.

5.5

5.8 (n=5)

Commercially available 5.5 (390 mg, 2 mmol, 1 eq) was dissolved in 10 mL of acetone and sodium iodide
(2.4 g, 16 mmol) was added. After reaction completion, as judged by AccuTOF-DART MS, the reaction
was concentrated to about 2 mL, diluted with water, extracted with 3 mL hexanes twice, 3 mL diethyl
ether twice, and 3 mL ethyl acetate twice. Organic portions from all three solvents exhibited product, so
they were combined and washed twice with a total of 25 mL sodium thiosulfate, which turned the
organic layer from yellow to clear in color. The organic layer was dried with sodium sulfate and dried
under vacuum, giving 5.8 as a white solid (n = 5, 460 mg, 90%).
1

H NMR (500 MHz, CDCl3) δ 10.85 (s, 1H), 3.19 (t, J = 7.0 Hz, 2H), 2.38 (t, J = 7.4 Hz, 2H), 1.85 (p, J

= 7.1 Hz, 2H), 1.67 (p, J = 7.5 Hz, 2H), 1.52 – 1.40 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 33.83, 33.05,
30.92, 29.86, 23.55, 6.41.
11-Iodoundecanoic acid

5.5

5.8 (n=10)
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5.5

5.6
5.7

5.5

5.8

5.9
5.10

Figure 5.2: Synthesis of terminal azide PC or terminal alkyne PC.
ω-Bromocarboxylic acid 5.5 can be derivatized with an azide to produce 5.6 for further work to make
PC analogue 5.7. Otherwise 5.5 can be activated to the better leaving iodide group 5.8, then lithium
acetylide will give the alkynoic acid 5.9, and final coupling will give 5.10.
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11-Iodoundecanoic acid

5.5

5.8 (n=10)

Commercially available 5.5 (390 mg, 2 mmol, 1 eq) was dissolved in 10 mL of acetone and
sodium iodide (2.4 g, 16 mmol) was added. After reaction completion, as judged by AccuTOF-DART MS,
the reaction was concentrated to about 2 mL, diluted with water, extracted with 3 mL hexanes twice, 3
mL diethyl ether twice, and 3 mL ethyl acetate twice. Organic portions from all three solvents exhibited
product, so they were combined and washed twice with a total of 25 mL sodium thiosulfate, which
turned the organic layer from yellow to clear in color. The organic layer was dried with sodium sulfate
and dried under vacuum, giving 5.8 as a white solid (n = 10, 533 mg, 85%).
1

H NMR (500 MHz, CDCl3) δ 11.56 (s, 1H), 3.17 (t, J = 7.0 Hz, 2H), 2.33 (t, J = 7.5 Hz, 2H), 1.80 (p, J

= 7.1 Hz, 2H), 1.61 (p, J = 7.4 Hz, 2H), 1.41 – 1.22 (m, 12H). 13C NMR (126 MHz, CDCl3) δ: 180.54, 34.10,
33.51, 30.45, 29.29, 29.26, 29.14, 28.98, 28.47, 24.60, 7.23.
10-Azodecanoic acid

5.5

5.6

Commercially available 5.5 (1 g, 251 mmol, 1 eq) was dissolved in 25 mL dimethylsulfoxide,
along with sodium azide (1.33 g, 19.8 mmol, 5 eq). After completion, the reaction was diluted with
water, which caused an exothermic reaction. After the reaction cooled, the aqueous layer was acidified
to pH 1 and extracted with ethyl acetate twice. The organic layer was washed with saturated sodium
chloride and dried with sodium sulfate. After decanting and drying under vacuum, the weight was found
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to be more than the theoretical yield. Chromatography with 50% ethyl acetate/hexanes gave the
product 5.6 (512.0 mg, 60% yield).
1

H NMR (300 MHz, CDCl3) δ 10.84 (s, 1H), 3.25 (t, J = 6.9 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.73 –

1.51 (m, 4H), 1.30 (s, 10H). 13C NMR (75 MHz, CDCl3) δ 180.35, 51.43, 34.06, 29.21, 29.09, 29.04, 28.96,
28.79, 26.65, 24.60.
5.5 Biotin-Azide Linker
Biotin-azide linker 5.18, which was also been previously synthesized in the Stubbs lab to
efficiently link biotin to a thalidomide derivative,129 has also been synthesized by a different route and is
currently in use by our laboratory (Figure 5.3). Commercially available diamine 5.11 with ethylene glycol
units was protected on one terminus with a tert-butoxycarbonyl (Boc) group to yield 5.13. Amino
conversion to azide was carried out with an azide transfer reagent, either in-situ with
trifluoromethanesulfonyl azide (Tf-N3)130 or a shelf-stable imidazole azide (Im-N3)131. The Tf-N3 produced
the best results, although the hazards are higher, as azides are known to be potentially explosive. Once
the azide 5.15 was produced, the Boc group was removed to 5.17, and biotin was attached via a
pentafluorophenyl ester 5.16 to 5.18. Several novel stains were used in this synthesis, including ones for
biotin132 or azides.133
5.6 Methods and Materials (Biotin-Azide)
Biotin pentafluorophenyl ester
5.14

5.12

5.16
Biotin (5.12, 1.00 g, 4.093 mmol) was added to 20 mL of DMF and heated to 80°C in a 50 mL
round bottom flask. After dissolution, the reaction was cooled to room temperature (23° C), and
triethylamine (1 mL) was added. Pentafluorophenyl trifluoroacetate (1 mL) was then added. The
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solution turned orange and then pink. After one hour, the DMF was distilled and the resulting solids
were washed with diethyl ether to give crude 5.16 (781 mg, 46%). Because of the high polarity of this
compound, it was directly used for the next reaction.
1

H NMR (500 MHz, DMSO-d6) δ: 6.26 (dd, J = 36.9, 8.4 Hz, 2H), 4.18 (t, J = 6.2 Hz, 1H), 4.09 – 3.93

(m, 1H), 2.97 (dd, J = 9.1, 4.8 Hz, 1H), 2.81 – 2.58 (m, 2H), 2.51 – 2.40 (m, 1H), 2.06 (t, J = 7.3 Hz, 1H),
1.55 (d, J = 6.3 Hz, 2H), 1.47 – 1.25 (m, 2H), 1.25 – 1.12 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 174.62,
169.66, 162.93, 61.20, 59.35, 55.53, 55.40, 33.61, 32.44, 28.25, 28.16, 28.04, 27.83, 24.65, 24.42, 8.74.
tert-Butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate. Compound 5.13.

5.11

5.13

Diamine 5.11 (9.54 mL, 43.53 mmol), triethylamine (400 μL, 55.38 mmol), and 25 mL of
methanol were combined together. Di-tert-butyl dicarbonate (946 mg, 4.34 mmol, 1 eq) was then added
in 15 mL of methanol dropwise over 40 minutes. The reaction was stirred overnight and then
concentrated with rotary evaporation. Column chromatography with 10:40:50 triethylamine/ethyl
acetate/methanol, then a second column with 89:10:1 CHCl3/MeOH/NH4OH produced product 5.13 as a
slightly yellowish oil, as detected by ninhydrin (1.19 g, 85%).

1

H NMR (500 MHz,CDCl3) δ 3.69 (t, J = 5.5 Hz, 2H), 3.64 (s, 6H), 3.62 – 3.59 (m, 2H), 3.55 (t, J =

6.0 Hz, 2H), 3.20 (dd, J = 7.8, 4.4 Hz, 2H), 2.08 – 2.00 (m, 2H), 1.77 (p, J = 6.4 Hz, 2H), 1.43 (s, 9H). 13C
NMR (500 MHz, CDCl3) δ 156.06, 78.66, 70.53, 70.49, 70.14, 70.10, 69.51, 69.39, 39.56, 33.24, 29.51.
HRMS-DART [M-H]+ calcd for C15H32N2O5, 321.2384; found 321.2385.

Tert-butyl (3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propyl)carbamate

5.13

5.15
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5.11

5.13
5.11

5.13
5.12

5.15
5.14
5.17

5.16

5.18
Figure 5.3: Synthesis of Biotin-TEG-Azide
Activated of biotin (5.12) with trifluoropentafluorophenyl ester gave biotin pentafluorophenyl ester
(5.16). Separately, diamine 5.11 was selectively protected on on end to produce 5.13. An azide
transfer reagent then gave 5.15, and deprotection of the Boc group gave 5.17. Reaction of this
compound with the activated 5.16 then produced biotin-TEG-azide 5.18.
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Amine 5.13 (319 mg, 0.9946 mmol), sodium bicarbonate (280 mg, 0119 mmol), and copper(II)
sulfate (7.0 mg, 0.0280 mmol) were added to 1 mL of water and 7 mL of methanol. To this 1.7 mL of
trifluoromethanesulfonyl azide, prepared from a literature procedure,130 was added. After 6 hours,
AccuTOF-DART MS revealed the disappearance of the amine. Concentration via rotary evaporation and
column chromatography with 10-25% ethyl acetate/hexanes gave product 5.15 as a clear oil, as judged
by a TLC stain for azides.133 (253 mg, 73%).
1

H NMR (300 MHz, CDCl3) δ: 5.11 (s, 1H), 3.70 – 3.49 (m, 12H), 3.40 (t, J = 6.7 Hz, 2H), 3.22 (q, J =

6.3 Hz, 2H), 1.86 (p, J = 6.4 Hz, 2H), 1.76 (p, J = 6.2 Hz, 2H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3) δ:
70.56, 70.52, 70.31, 70.15, 69.43, 67.82, 48.43, 39.48, 32.78, 29.10. HRMS-DART [M-H]+ calcd for
C15H30N4O5, 347.2289; found 347.2286.
3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propan-1-amine

5.17
5.15
Azide 5.17 (234 mg, 1.05 mmol) was dissolved in 2.5 mL of ethanol, and 0.5 mL of concentrated
hydrochloric acid was slowly added, along with 2.5 mL of diethyl ether. After disappearance of the
starting material was confirmed by TLC, the reaction was concentrated under rotary evaporation. Then
to neutralize the hydrochloric acid, 2.3 mL of sodium bicarbonate was added to the residue, upon which
bubbling occurred. The organic material was extracted with dichloromethane (2 x 20 mL), dried with
sodium sulfate, and decanted. The resulting solution was dried under rotary evaporation to give the
product 5.17 (91 mg, 55%).
1

H NMR (300 MHz, CDCl3) δ 5.11 (s, 12H), 3.70 – 3.49 (m, 2H), 3.40 (t, J = 6.7 Hz, 2H), 3.22 (q, J =

6.3 Hz, 2H), 1.86 (p, J = 6.4 Hz, 2H), 1.76 (p, J = 6.2 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 70.56, 70.52,
70.31, 70.15, 69.43, 67.82, 48.43, 39.48, 32.78, 29.10. HRMS-DART [M-H]+ calcd for C10H22N4O3,
247.1765; found 247.1781.
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N-(3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propyl)-5-(biotin)pentanamide

5.17
5.18
Compound 5.18 (60.5 mg, 0.1535 mmol) was dissolved in 1 mL dry dimethylformamide. The
azide 5.17 (41.6 mg, 0.1689 mmol, 1.1 eq) was separately added to 1 mL dry dimethylformamide, along
with 22 μL of triethylamine. The solution of 5.18 was chilled in a dry ice-acetone bath, and the azide
solution was added to it. After disappearance of product was detected in the AccuTOF DART-MS, a
spatula-tip full of dimethylaminopyridine was added to the solution. The next day the
dimethylformamide was removed by vacuum distillation, and column chromatography with 25-50%
methanol/ethyl acetate was used. Visualization of the product on TLC was aided by a cinnamaldehyde
stain to detect biotin substrates.132 The azide stains mentioned earlier also gave visual confirmation of
products.133 The relevant fractions were collected and dried under vacuum to give product 5.18 as an
orange solid (21.1 mg, 29%).
1

H NMR (500 MHz, CD3OD) δ 4.50 (dd, J = 7.8, 5.2 Hz, 1H), 4.31 (dd, J = 7.9, 4.4 Hz, 1H), 3.64 (dh,

J = 4.8, 1.4 Hz, 4H), 3.61 – 3.58 (m, 4H), 3.56 (t, J = 6.1 Hz, 2H), 3.53 (t, J = 6.2 Hz, 2H), 3.40 (t, J = 6.7 Hz,
2H), 3.26 (t, J = 6.8 Hz, 2H), 3.21 (ddd, J = 8.9, 5.7, 4.4 Hz, 1H), 2.93 (dd, J = 12.7, 5.0 Hz, 1H), 2.71 (d, J =
12.7 Hz, 1H), 2.20 (t, J = 7.4 Hz, 2H), 1.83 (p, J = 6.4 Hz, 2H), 1.76 (p, J = 6.5 Hz, 3H), 1.72 – 1.55 (m, 3H),
1.44 (p, J = 7.8 Hz, 2H). 13C NMR (126 MHz, CD3OD) δ 175.96, 166.07, 71.53, 71.52, 71.27, 71.23, 69.94,
68.92, 63.37, 61.61, 56.99, 49.48, 41.04, 37.82, 36.85, 30.40, 30.15, 29.79, 29.50, 26.87.
5.7 Azobenzenes for Chiral Polarimetry
Azobenzenes play a big role in the scientific community, and different types and some
applications have been reviewed by Hamon et al.134 The property that makes them unique is that under
ultraviolet light, they isomerize from the E form to the higher energy Z form. Even more unique is that
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some azobenzenes can be converted back to the E form by irradiation with visible light. One family of
compounds that exhibits these characteristics include the o-fluoroazobenzenes and their derivatives.135
These fluorinated compounds (5.23) are being used in a collaboration with Dr. Bob Compton to test the
effect of chiral plane-polarized light (Figure 5.4), along with an methylated azobenzene (5.23), a nitrated
azobenzene (5.29), and a combination of the previous two (5.27). The goal of these compound is to find
a combination that forms a chiral enantiomers under UV light, due to sterics or electronics of the
molecule causing the rings to remain in a staggered position (Figure 5.4). The first three of these
compounds were synthesized in one step by oxidative coupling from the corresponding aniline. The last
compound was synthesized in several steps from 2,5-dimethylaninline. The yields of all oxidative
coupling reactions, however, were moderate to low yields under all conditions attempted. Either the
reagents did not convert the starting materials well, or they converted them to a side product, such as
phenazines.136
5.8 Materials and Methods (Azobenzenes)
2,2’,6,6’-Tetrafluoroazobenzene.

5.30

5.31
2,6-Difluoroaniline (5.30, 662 uL, 1 g, 7.745 mmol) was dissolved in 40 mL of dichloromethane.
Then using a mortar and pester, equal weight iron(II) sulphate heptahydrate and potassium
permanganate (8 g total) were ground together and added into the flask. The reaction was heated to 40°
C. The next day the reaction was filtered through Celite and washed with dichloromethane. Column
chromatography with 50% dichloromethane in hexanes, then dichloromethane gave product 5.31 (113
mg, 11%).
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5.19

5.20

5.21
Figure 5.4: Proposed enantioselectivity of polarized light
Electronic or steric effects of the substituents of the azobenzene compounds could produce a nonmeso form of the higher energy Z form of the azobenzenes, and with chiral light can produce
enantiomers.
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5.22

5.24

5.23

5.25

5.26
5.27

5.28
5.29

5.30

5.31
Figure 5.5: Synthesis of azobenzenes for the production of chiral enantiomers under UV light
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1

H NMR (300 MHz, CDCl3) δ: 7.45-7.28 (m, 2H), 7.13-6.98 (m, 4H). 13C NMR (75 MHz, CDCl3) δ:

157.28 (d, J = 4.1 Hz), 153.82 (d, J =4.2 Hz), 131.48 (t, J=10.5 Hz), 112.60 (dd, J=20.7, 3.4 Hz). 19F (282
MHz, CDCl3) δ: -124.94, referenced to 2,2,2-trifluoroethanol as an external standard. (There is a minor
peak due to a partial existence of the E isomer of the compound.) HRMS-DART: [M]-, calcd for C12H6F4N2,
254.0467, found 254.0467.
2,2’,6,6’-Tetramethylazobenzene.

2,6-Dimethylaniline (2 g, 2.03 mL, 16.5 mmol) was added to 125 mL of dichloromethane. With a
mortar and pestle, copper sulfate pentahydrate (11.8 g, 0.0472 mmol) and potassium permanganate
(11.1 g, 5.8 mmol) were ground together and then added to the solution. The next day, the reaction was
filtered through Celite, rinsed with dichloromethane, and concentrated under rotary evaporation.
Column chromatography with 25% ethyl acetate/hexanes produced product 5.23 (524 mg, 27%).
1

H NMR (300 MHz, CDCl3) δ: 7.18 – 7.12 (m, 6H), 2.42 (s, 12H).

13

C NMR (75 MHz, CDCl3) δ:

151.31, 131.16, 129.28, 128.30, 19.70. AccuTOF DART MS: [M]-, calcd for C16H18N2, 238.14700; found
238.1466.
4,4’-Dinitroazobenzene.

4-Nitroaniline (217 mg, 1 eq), copper(I) bromide (43 mg, 0.10 eq), and pyridine (72 uL, 0.30
mmol) were added to 12 mL of toluene. The reaction was refluxed at 60° C under air, then a balloon
with oxygen was used when TLC showed little conversion. After 18 hours of reflux at 75 C with little
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conversion, 43 mg more of copper(I) bromide and also 153 mg of L-ascorbic acid were added. After 1
hour, more conversion was evident. Then 110 mg more of L-ascorbic acid was added and the reaction
was refluxed overnight. The reaction was then concentrated, column chromatography with 50 to 75%
dichloromethane/hexanes gave product (116 mg, 54%).
1

H NMR (300 MHz, CDCl3) δ: 8.46-8.41 (m, 2H), 8.14-8.08 (m, 2H). 13C (126 MHz, CDCl3) 155.12,

149.50, 124.50, 124.00. HRMS-DART [M]-, calcd for C12H8N4O2, 272.0546; found 272.0540.
2,2’,6,6’-Tetramethyl-4,4’-Dinitroazobenzene.

2,6-dimethyl-4-nitroaniline (417.9 mg, 2.515 mmol) was dissolved in dichloromethane. A ground
mixture of equal weight postassium permanganate and copper(II) sulfate heptahydrate (4g total) was
added to the solution. The next day, the reaction was filter through Celite and concentrated. Column
chromatography with a 10-25% dichloromethane/hexanes gradient gave pure product 5.27. (32.8 mg,
29%).
1

H NMR (500 MHz, CDCl3) δ 8.06 (s, 4H), 2.47 (s, 12H).

13

C NMR (126 MHz, CDCl3) δ 154.84,

146.91, 132.58, 124.45, 19.60. AccuTOF DART: [M]-, calcd for C16H16N4O4, 328.1172; found 328.1111.
N-(2,6-dimethylphenyl)-4-methylbenzenesulfonamide. Compound 5.24.

2,6-Dimethylamiline (2.03 mL, 2.0 g, 16.50 mmol, 1 eq) was added to pyridine (8 mL, 6 eq). Then
p-toluenesulfonyl chloride (4.68 g, 24.55 mmol, 1.5 eq) was added to the solution. The reaction was
refluxed at 80° C for slightly over one hour and cooled to room temperature. The reaction was then
precipitated into ice, and the solids were collected on a fritted filter, rinsing them with ice cold water.
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The solids were partitioned between water and ethyl acetate, and the aqueous layer was extracted with
ethyl acetate (2 x 50 mL). The organic layer was then washed with 50 mL saturated sodium chloride,
dried with sodium sulfate, and decanted. After drying using rotary evaporation, the resulting white
solids were found to be product 5.24 as a white solid (3.97 g, 88%).
1

H NMR (300 MHz, CDCl3) δ 7.60 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.7 Hz, 2H), 7.13 – 6.94 (m, 3H),

6.42 (s, 1H), 2.41 (s, 3H), 2.04 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 143.62, 137.79, 132.61, 129.63, 128.76,
127.74, 127.17, 104.99, 21.58, 18.74. HRMS-DART [M+H]+, calcd for C15H8N4O4, 276.1053, found
276.1136.
N-(2,6-Dimethyl-4-nitrophenyl)-4-methylbenzenesulfonamide.

5.32
To

25

mL

of

a

60%

aqueous

acetic

5.33
acid

solution

was

added

N-(2,6-

dimethylphenyl)benzenesulphonamide (2.0 g, 7.263 mmol, 1 eq). To this was added sodium nitrite
slowly (100 mg, 1.453 mmol, 0.2 eq). Concentrated nitric acid (1.0 mL, 2.2 eq) was then added dropwise.
The reaction was refluxed at 80° C for 30 minutes, after which it was washed with ethyl acetate (2 x 50
mL). The organic layer was then washed with 100 mL of 10% w/v sodium hydroxide and then dried with
sodium sulfate and decanted. Column chromatography with dichloromethane, then a second column
with 25% dichloromethane-hexanes gave product 5.25 as a white solid (951 mg, 41%).
1

H NMR (300 MHz, CDCl3) δ: 7.89 (s, 2H), 7.61 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.7 Hz, 2H), 2.45 (s,

3H), 2.16 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 144.49, 139.25, 138.70, 137.20, 129.94, 127.06, 123.53,
105.00, 21.63, 19.13.
2,6-dimethyl-4-nitroaniline. Compound 5.25.
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5.24
5.25
N-(2,6-dimethylphenyl)-4-methylbenzenesulfonamide (932 mg, 2.91 mmol) was added to 10 mL
of concentrated sulfuric acid in two separate batches and refluxed for 75 minutes. The combined
reaction was filtered and the solids collected. The solids were then basified with saturated sodium
bicarbonate and extracted with ethyl acetate (2 x 50 mL). The organic layer was dried with magnesium
sulfate and filtered. After concentration and drying under rotary evaporation, the resulting material was
found to be product 5.25 as a yellow solid (418 mg, 87%).
5.9 N-Nosylated Alanine Derivatives
N-Nosyl alanine derivatives were also synthesized for studies of light with chiral molecules, in
order to test if light has specific interactions with one enantiomer versus another. These compounds
were synthesized in a collaborative work with Dr. Compton to characterize the photoelectric spectrum
and collision-induced dissociation of these compounds and two others.137 N-nosyl dervatives of alanine
have been synthesized previously. Gioia et al.138 utilized them as an efficient protecting group of the Nterminus in the synthesis of a peptides, using mercaptoacetic acid and sodium ethoxide to cleave it
when necessary. Both were synthesized in one step from D- or L-alanine. Rotations were measured
afterwards to ensure they were enantiomers. (D = -76.9, L = + 80.6)
5.10 Methods and Materials (N-Nosylated Alanine Derivatives)
((4-nitrophenyl)sulfonyl)-L-alanine. Compound 5.37.
L-Lysine (5.36, 0.21 g, 2.36 mmol) was dissolved in 5 mL of 1M sodium hydroxide. After 10
minutes, p-nosyl chloride (0.82 g) was added. After 5 hours, insoluble solids were seen in the aqueous
solution. The aqueous solution was washed with diethyl ether (3 x 20 mL). The aqueous layer was then
acidified with 2 M hydrochloric acid to pH 1, as tested by litmus paper. The aqueous layer was then
washed with ethyl acetate (3 x 20 mL). The organic layer was then dried with magnesium sulfate and
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filtered. Column chromatography with 5% methanol–dichloromethane gave the product 5.37 as a yellow
solid (265 mg, 53%).
1

H NMR (500 MHz, DMSO-d6) δ 8.60 – 8.51 (m, 1H), 8.37 (d, J = 8.8 Hz, 1H), 8.02 (d, J = 8.7 Hz, 1H), 3.91 –
13

3.81 (m, 1H), 1.18 (d, J = 7.2 Hz, 2H). C NMR (500 MHz, DMSO-d6) δ 172.98, 149.99, 128.10, 124.43, 51.37,

18.50. [𝛼]20
𝐷 = −80.6°
((4-nitrophenyl)sulfonyl)-D-alanine.
D-Lysine (5.38, 0.21 g, 2.36 mmol) was dissolved in 5 mL of 1M sodium hydroxide. After 10
minutes, p-nosyl chloride (0.82 g) was added. After 5 hours, insoluble solids were seen in the aqueous
solution. The aqueous solution was washed with diethyl ether (3 x 20 mL). The aqueous layer was then
acidified with 2 M hydrochloric acid to pH 1, as tested by litmus paper. The aqueous layer was then
washed with ethyl acetate (3 x 20 mL). The organic layer was then dried with magnesium sulfate and
filtered. Colum chromatography with 5% methanol/dichloromethane gave the product (317 mg, 64%).
1

H NMR (500 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.39 (J=8.9 Hz, 1H), 8.03 (J=8.3 Hz, 1H), 3.87 (q,

J=7.1 Hz, 1H), 1.19 (J=7.2 Hz, 2H).

13

C NMR (500 MHz, DMSO-d6) δ 172.97, 149.50, 146.98, 128.10,

124.43, 51.37, 18.50. HRMS-DART: [M-H]-, calcd for C9H10N2O6S, 273.0187; found 273.0577. [𝛼]20
𝐷 =
−76.9°
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5.34

5.35

5.36

5.37
Figure 5.6: N-Nosylation of D/L alanine
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Spectra 5.1: 1H NMR. Compound 5.4. Dibenzocyclooctyne-polyethylene glycol2000-phosphatidylethanolamine (DBCO-PEG-PE)
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Spectra 5.2: MALDI-MS of Compound 5.3 (H2N-PEG2000-PE)
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Spectra 5.3: MALDI-MS of Compound 5.4 (DBCO-PEG2000-PE)
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Spectra 5. 4: MALDI-MS of Compound 5.4 (DBCO-PEG2000-PE) + PEG 3400 reference
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Spectra 5.5: 1H NMR. Compound 5.1. DBCO-acid
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Spectra 5.6: 13C NMR. Compound 5.1. DBCO-acid
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Spectra 5.7: 1H NMR. Compound 5.8 (n=5). 6-Iodohexanoic acid
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Spectra 5.8: 13C NMR. Compound 5.8 (n=5). 6-Iodohexanoic acid
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Spectra 5.9: gCOSY NMR. Compound 5.8 (n=5). 6-Iodohexanoic acid
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Spectra 5.10: gHSQC NMR. Compound 5.8 (n-5). 6-Iodohexanoic acid
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Spectra 5.11: gHMBC NMR. Compound 5.8 (n=5). 6-Iodohexanoic acid
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Spectra 5.12: 1H NMR. Compound 5.8 (n=10). 11-Iodoundecanoic acid
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Spectra 5.13: 13C NMR. Compound 5.8 (n=10). 11-Iodoundecanoic acid
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Spectra 5.14: 1H NMR. Compound 5.6. 10-Azidodecanoic acid
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Spectra 5.15: 13C NMR. Compound 5.6. 10-Azidodecanoic acid
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Spectra 5. 16: 1H NMR (crude). Compound 5.16. Biotin pentafluorophenyl ester
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Spectra 5. 17: 13C NMR (crude). Compound 5.16. Biotin pentafluorophenyl ester
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Spectra 5.18: 1H NMR. Compound 5.13. tert-Butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate
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Spectra 5.19: 13C NMR. Compound 5.13. tert-Butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate
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Spectra 5.20: 1H NMR. Compound 5.15. tert-Butyl (3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propyl)carbamate
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Me2CO

Spectra 5.21: 13C NMR. Compound 5.15. Tert-butyl (3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propyl)carbamate
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Spectra 5.22: 1H NMR. Compound 5.17. 3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propan-1-amine
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Spectra 5.23: 13C. Compound 5.17. 3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propan-1-amine
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Spectra 5.24: 1H NMR. Compound 5.18. N-(3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propyl)-5-(biotin)pentanamide
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Spectra 5.25: 13C NMR. Compound 5.18. N-(3-(2-(2-(3-azidopropoxy)ethoxy)ethoxy)propyl)-5-(biotin)pentanamide
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Spectra 5.26: 1H NMR. Compound 5.31. 2,2’,6,6’-Tetrafluoroazobenzene
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Spectra 5.27: 13C NMR. Compound 5.31. 2,2’,6,6’-Tetrafluoroazobenzene
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Spectra 5.28. 19F NMR. Compound 5.31. 2,2’,6,6’-Tetrafluoroazobenzene
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Spectra 5.29: 1H NMR. Compound 5.23. 2,2’,6,6’-Tetramethylazobenzene
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Spectra 5.30: 13C NMR. Compound 5.23. 2,2’,6,6’-Tetramethylazobenzene
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Spectra 5.31. 1H NMR. Compound 5.29. 4,4'-Dinitroazobenzene
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Spectra 5.32: 13C NMR. Compound 5.29. 4,4'-Dinitroazobenzene
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Spectra 5.33: 1H NMR. Compound 5.25. N-(2,6-dimethylphenyl)-4-methylbenzenesulfonamide
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Spectra 5.34: 13C NMR. Compound 5.25. N-(2,6-dimethylphenyl)-4-methylbenzenesulfonamide
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Spectra 5.35: 1H NMR. Compound 5.25. N-(2,6-dimethyl-4-nitrophenyl)-4-methylbenzenesulfonamide
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Spectra 5.36: 13C NMR. Compound 5.25. N-(2,6-dimethyl-4-nitrophenyl)-4-methylbenzenesulfonamide
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Spectra 5.37: 1H NMR. Compound 5.26. 2,6-dimethyl-4-nitroaniline
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Spectra 5.38: 13C NMR. Compound 5.26. 2,6-dimethyl-4-nitroaniline
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Spectra 5.39: 1H NMR. Compound 5.27. 2,2',6,6'-Tetramethyl-4,4'-dinitroazobenzene
222

Spectra 5.40: 13C NMR. Compound 5.27. 2,2',6,6'-Tetramethyl-4,4'-dinitroazobenzene
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Spectra 5.41: 1H NMR. Compound 5.37. ((4-nitrophenyl)sulfonyl)-L-alanine
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Spectra 5.42: 13C NMR. Compound 5.37. ((4-nitrophenyl)sulfonyl)-L-alanine
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Spectra 5.43: 1H NMR. Compound 5.39. ((4-nitrophenyl)sulfonyl)-D-alanine
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Spectra 5.44: 13C NMR. Compound 5.39. ((4-nitrophenyl)sulfonyl)-D-alanine
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